Lab Personnel

Lab Alumni - Postdoctoral

Mikhail Blagosklonny, MD, PhD
1995 - 97, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Associate Professor, Dept. of Medicine, NY Medical College
2005 - Senior Scientist at Ordway Research Institute
2009 - Professor, Roswell Park Cancer Institute
Editor-in-Chief, Cell Cycle

Original Publications
Blagosklonny, M.V., and El-Deiry, W.S. In-Vitro Evaluation of a p53-Expressing Adenovirus as an Anticancer Drug. Int. J. Cancer, 67:386-392, 1996.
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Suppression of Cancer Cell Growth by Adenovirus Expressing p21WAF1/CIP1 Deficient in PCNA Interaction. Clin. Cancer Res., 2:1221-1230, 1996.
Blagosklonny, M.V., Wu, G.S., Omura, S., and El-Deiry, W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Comm., 227:564-569, 1996.
Blagosklonny, M.V., Giannakakou, P., El-Deiry, W.S., Kingston, D., Neckers, L., and Fojo, T. Activation of Raf-1/bcl-2 pathway by microtubule active drugs links microtubule damage to cell death. Cancer Res., 57:130-135, 1997.
Blagosklonny, M.V., Wu, G.S., Somasundaram, K., and El-Deiry, W.S. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. Int. J. Oncol., 11:1165-1170, 1997.
Blagosklonny, M.V., Prahbu, N.S., and El-Deiry, W.S. Defects in p21WAF1/CIP1, Rb, and c-myc Signaling in Phorbol Ester-resistant Cancer Cells. Cancer Res., 57:320-325, 1997.
Blagosklonny, M.V., and El-Deiry, W.S. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int. J. Cancer, 75:933-940, 1998.
Abstracts
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Truncated p21-Adenovirus Bypass of p53 Resistance in the Therapy of Human Cancer. Proc. AACR 37:346 (Abstract No. 2360), 1996.
Blagosklonny, M.V., and El-Deiry, W.S. Defects in Raf-1>>p21WAF1/CIP1>Rb>c-myc Signaling in PMA-resistant Cancer Cells. Proc. AACR 37:426 (Abstract No. 2908), 1996.

Yi-Xin Zeng, MD, PhD
1995 - 97, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Director, Cancer Research Institute and Cancer Center, Sun Yat Sen University, Guangzhou, China
President, Sun Yat Sen University
Editor-in-Chief, Chinese Journal of Cancer
President, Peking Union Medical College
Member, Chinese Academy of Sciences

Orginal Publications
Zeng, Y.-X., and El-Deiry, W.S. Regulation of p21WAF1/CIP1 Expression by p53-independent Pathways. Oncogene, 12:1557-1564, 1996.
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Suppression of Cancer Cell Growth by Adenovirus Expressing p21WAF1/CIP1 Deficient in PCNA Interaction. Clin. Cancer Res., 2:1221-1230, 1996.
Shick, L., Carmen, J., Choi, J., Somasundaram, K., Burrell, M., Hill, D.E., Zeng, Y.-X., Wang, Y., Wiman, K.G., Salhany, K., Kadesch, T.R., Monroe, J., Donehower, L.A., and El-Deiry, W.S. Decreased Ig deposition in tumors and increased immature B cells in p53-/- mice. Cell Growth and Diff., 8:121-131, 1997.
Zeng, Y.-X., Somasundaram, K., and El-Deiry, W.S. AP-2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genet., 15:78-82, 1997.
Zeng, Y.-X., Somasundaram, K., Prabhu, N.S., Krishnadasan, R., and El-Deiry, W.S. Detection and analysis of living growth inhibited mammalian cells following transfection. BioTechniques, 23:88-94, 1997.
Zeng, Y.-X., Prabhu, N.S., Meng, R., and El-Deiry, W.S. Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int. J. Oncol., 11:221-226, 1997.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, H., Peng, Y., Zhang, H., Wu, G.S., Licht, J.D., Weber, B.L., and El-Deiry, W.S. Arrest of the cell cycle by the tumour suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIP1. Nature, 389:187-190, 1997.
Yang, W.-L., Zeng, Y.-X., El-Deiry, W.S., Nason-Burchenal, K., Dmitrovsky, E., and Chen, K.-V. Transcriptional activation of the cyclin-dependent kinase inhibitor p21 by PML/RAR. Mol. Cell Biol. Res. Comm., 1:125-131, 1999.
Abstracts
Zeng, Y.-X., and El-Deiry, W.S. Multiple Signaling Pathways Transcriptionally Regulate p21WAF1/CIP1 Expression. AACR Special Conference "Cancer: The Interface Between Basic and Applied Research," Baltimore, Maryland, 1995.
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Truncated p21-Adenovirus Bypass of p53 Resistance in the Therapy of Human Cancer. Proc. AACR 37:346 (Abstract No. 2360), 1996.
Zeng, Y.-X., Somasundaram, K., and El-Deiry, W.S. AP-2 transactivates p21WAF1/CIP1 expression and inhibits growth of human cancer cells. Cold Spring Harbor Meeting on Cancer Genetics and Tumor Suppressor Genes, 1996.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Wu, G.S., Peng, Y., Zhang, H., Licht, J.D., El-Deiry, W.S. and Weber, B.L. BRCA1 inhibition of the cell cycle requires p21WAF1/CIP1. Cancer Genetics and Tumor Suppressor Genes Conference, Hood College, Frederick, MD, 1997.

Lawton Shick, MD
1995 - 97, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Department of Medicine (GI), University of Massachusetts

Orignal Publications
Shick, L., Carmen, J., Choi, J., Somasundaram, K., Burrell, M., Hill, D.E., Zeng, Y.-X., Wang, Y., Wiman, K.G., Salhany, K., Kadesch, T.R., Monroe, J., Donehower, L.A., and El-Deiry, W.S. Decreased Ig deposition in tumors and increased immature B cells in p53-/- mice. Cell Growth and Diff., 8:121-131, 1997.
Abstracts
Shick, L., Donehower, L.A., and El-Deiry, W.S. Immunoglobulin Deposition in Tumors Derived from p53 +/- but not p53 -/- Mice. Proc. AACR 37:563 (Abstract No. 3861), 1996.

Kumar Somasundaram, DVM, PhD
1995 - 99, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Indian Institute of Science
2006 - Associate Professor, Microbiology, IIS
2012 - Professor, Indian Institute of Science

Orginal Publications
Somasundaram, K., and El-Deiry, W.S. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene, 14:1047-1058, 1997.
Shick, L., Carmen, J., Choi, J., Somasundaram, K., Burrell, M., Hill, D.E., Zeng, Y.-X., Wang, Y., Wiman, K.G., Salhany, K., Kadesch, T.R., Monroe, J., Donehower, L.A., and El-Deiry, W.S. Decreased Ig deposition in tumors and increased immature B cells in p53-/- mice. Cell Growth and Diff., 8:121-131, 1997.
Zeng, Y.-X., Somasundaram, K., and El-Deiry, W.S. AP-2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genet., 15:78-82, 1997.
Zeng, Y.-X., Somasundaram, K., Prabhu, N.S., Krishnadasan, R., and El-Deiry, W.S. Detection and analysis of living growth inhibited mammalian cells following transfection. BioTechniques, 23:88-94, 1997.
Blagosklonny, M.V., Wu, G.S., Somasundaram, K., and El-Deiry, W.S. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. Int. J. Oncol., 11:1165-1170, 1997.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, H., Peng, Y., Zhang, H., Wu, G.S., Licht, J.D., Weber, B.L., and El-Deiry, W.S. Arrest of the cell cycle by the tumour suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIP1. Nature, 389:187-190, 1997.
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Weber, B.L., and El-Deiry, W.S. The tumor suppressor BRCA1 physically interacts with p53 and stimulates gatekeeper-dependent transcription of bax and p21WAF1/CIP1. Oncogene, 16:1713-1721, 1998.
Prabhu, N.S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., and El-Deiry, W.S. p73, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol., 13:5-9, 1998.
Mitra, J., Dai, C.Y., Somasundaram, K., El-Deiry, W.S., Satyamoorthy, K., Herlyn, M., and Enders, G.H. Induction of p21(WAF1/CIP1) and inhibition of cdk2 mediated by the tumor suppressor p16(INK4a). Mol. Cell. Biol., 19:3916-3928, 1999.
Somasundaram, K., MacLachlan, T.K., Burns, T.F., Sgagias, M., Cowan, K., Weber,B.L., and El-Deiry, W.S. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene, 18:6605-6614, 1999.
Prabhu, N.S., Somasundaram, K., Tian, H., Enders, G.H., Satyamoorthy, K., Herlyn, M., and El-Deiry, W.S. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int. J. Oncol., 15:209-216, 1999.
MacLachlan, T.K., Somasundaram, K., Sgagias, M., Shifman, Y., Muschel, R.J., Cowan, K.H., and El-Deiry, W.S. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem., 275:2777-2785, 2000.
Das, S., El-Deiry, W.S., and Somasundaram, K. Regulation of p53 homologue p73 by adenovirus oncogene E1A. J. Biol. Chem., 278:18313-18320, 2003.
Abstracts
Somasundaram, K., and El-Deiry, W.S. E1A inhibits p53-mediated transactivation and cell cycle checkpoint function through its N-terminus. Cold Spring Harbor Meeting on Cancer Genetics and Tumor Suppressor Genes, 1996.
Zeng, Y.-X., Somasundaram, K., and El-Deiry, W.S. AP-2 transactivates p21WAF1/CIP1 expression and inhibits growth of human cancer cells. Cold Spring Harbor Meeting on Cancer Genetics and Tumor Suppressor Genes, 1996.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Wu, G.S., Peng, Y., Zhang, H., Licht, J.D., El-Deiry, W.S. and Weber, B.L. BRCA1 inhibition of the cell cycle requires p21WAF1/CIP1. Cancer Genetics and Tumor Suppressor Genes Conference, Hood College, Frederick, MD, 1997.
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Weber, B.L., and El-Deiry, W.S. The BRCA1 tumor suppressor functions as a transcriptional coactivator with p53. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Mitra, J., Somasundaram, K., El-Deiry, W.S., Zhu, L., and Enders, G.H. Induction of p21CDKN1 and establishment of a reversible slow-growth state by the tumor suppressor p16CDKN2. Cold Spring Harbor meeting honoring James Watson, 1998.
Mitra, J., Somasundaram, K., El-Deiry, W.S. and Enders, G.H. Contribution of p21CDKN1 to p16CDKN2-mediated cell cycle inhibition in osteogenic sarcoma cells. Cell Cycle Meeting, Cold Spring Harbor Laboratory, May 1998.
Prasher, J., Hsieh, F-F, Somasundaram, K., El-Deiry, W., and Kelley, L. Activation of endogenous p53 during normal differentiation of pre-leukemic cells. Gordon Research conference, 1998.
Somasundaram, K., Weber, B.L., Seth, P.K., and El-Deiry, W.S. BRCA1 coactivates p53-mediated transcription by stabilizing p53 in an ARF-dependent manner. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 4789, April 1999.
MacLachlan, T.K., Somasundaram, K., Nei, T., Weber, B.L., Seth, P., and El-Deiry, W.S. Accumulation of p53 and activation of cellular genes by BRCA1. Workshop “p53: Twenty Years On,” May 1999, Trieste, Italy.

Gen Sheng Wu, MD, PhD
1995 - 99, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Karmanos Cancer Center, Wayne State University
2005 - Associate Professor, Karmanos Cancer Center, Wayne State University
Reviews Editor, Cancer Biology and Therapy

Original Publications
Wu, G.S., and El-Deiry, W.S. Apoptotic Death of Tumor Cells Correlates with Chemosensitivity, Independent of p53 or Bcl2. Clin. Cancer Res., 2:623-633, 1996.
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Suppression of Cancer Cell Growth by Adenovirus Expressing p21WAF1/CIP1 Deficient in PCNA Interaction. Clin. Cancer Res., 2:1221-1230, 1996.
McDonald, E.R., III, Wu, G.S., Waldman, T., and El-Deiry, W.S. Repair Defect in p21WAF1/CIP1-/- Cells. Cancer Res., 56:2250-2255, 1996.
Wu, G.S., and El-Deiry, W.S. p53 and chemosensitivity. Nature Medicine, 2:255-256, 1996.
Gartel, A.L., Serfas, M.S., Gartel, M., Goufman, E., Wu, G.S., El-Deiry, W., and Tyner, A.L. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp. Cell Res., 227:171-181, 1996.
Blagosklonny, M.V., Wu, G.S., Omura, S., and El-Deiry, W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Comm., 227:564-569, 1996.
Blagosklonny, M.V., Wu, G.S., Somasundaram, K., and El-Deiry, W.S. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. Int. J. Oncol., 11:1165-1170, 1997.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, H., Peng, Y., Zhang, H., Wu, G.S., Licht, J.D., Weber, B.L., and El-Deiry, W.S. Arrest of the cell cycle by the tumour suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIP1. Nature, 389:187-190, 1997.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics, 17:141-143, 1997.
Wu, G.S., Saftig, P., Peters, C. and El-Deiry, W.S. Potential role for Cathepsin D in p53-dependent tumor Suppression and chemosensitivity. Oncogene, 16:2177-2183, 1998.
Sheikh, M.S., Burns, T.F., Huang, Y., Wu, G.S., Amundson, S., Brooks, K.S., Fornace, A.J., Jr., and El-Deiry, W.S. p53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and TNF. Cancer Res., 58:1593-1598, 1998.
Pai , S.I., Wu, G.S., Ozoren, N., Wu, L., Jen, J., Sidransky, D., and El-Deiry, W.S. Germline loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res., 58:3513-3518, 1998.
Sun, S.-Y., Yue, P., Wu, G.S., El-Deiry, W.S., Shroot, B., Hong, W.K., and Lotan, R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene, 18:2357-2365, 1999.
Sun, S.-Y., Yue, P., Wu, G.S., El-Deiry, W.S., Shroot, B., Hong, W.K., and Lotan, R. Implication of p53 in mediating growth arrest and apoptosis induced by the synthetic retinoid CD437 in human H460 lung cancer cells. Cancer Res., 59:2829-2833, 1999.
Wu, G.S., Burns, T.F., McDonald, E.R., III, Meng, R.D., Kao, G., Muschel, R., Yen, T., and El-Deiry, W.S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not G1 arrest. Oncogene, 18:6411-6418, 1999.
Wu, G.S., Burns, T.F., Zhan, Y., Alnemri, E.S., and El-Deiry, W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 TRAIL death receptor. Cancer Res., 59:2770-2775, 1999.
Fisher, M.J., Virmani, A. K., Wu, L., Sidransky, D., Gazdar, A.F., and El-Deiry, W.S. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clinical Cancer Research, 7:1688-1697, 2001.
Finnberg, N., Gruber, J.J., Fei, P., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., McKenna, W.G., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. DR5 knock-out mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol., 25:2000-13, 2005.
Kuribayashi, K., Krigsfeld, G., Wang, W., Xu, J., Mayes, P.A., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7:2034-2038, 2008.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Wu, G.S., and El-Deiry, W.S. Correlations between p53 Status, Bcl2 Expression, Apoptosis and Chemosensitivity of Human Cancer Cells In-vitro. Proc. AACR 37:422 (Abstract No. 2879), 1996.
Prabhu, N.S., Blagosklonny, M.V., Zeng, Y.-X., Wu, G.S., Waldman, T., and El-Deiry, W.S. Truncated p21-Adenovirus Bypass of p53 Resistance in the Therapy of Human Cancer. Proc. AACR 37:346 (Abstract No. 2360), 1996.
Wu, G.S., and El-Deiry, W.S. Novel genes upregulated in chemosensitive cancer cells following adriamycin treatment. Keystone Symposium on Growth Control, Copper Mountain, CO, 1997.
Wu, G.S. and El-Deiry, W.S. Role of Cathepsin D in p53-dependent apoptosis. Cancer Genetics and Tumor Suppressor Genes Conference, Hood College, Frederick, MD, 1997.
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Wu, G.S., Peng, Y., Zhang, H., Licht, J.D., El-Deiry, W.S. and Weber, B.L. BRCA1 inhibition of the cell cycle requires p21WAF1/CIP1. Cancer Genetics and Tumor Suppressor Genes Conference, Hood College, Frederick, MD, 1997.

Hui Tian, MD, PhD
1997 - 99, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Postdoctoral Researcher, Dept. of Radiation Oncology, Georgetown University

Original Publications
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Weber, B.L., and El-Deiry, W.S. The tumor suppressor BRCA1 physically interacts with p53 and stimulates gatekeeper-dependent transcription of bax and p21WAF1/CIP1. Oncogene, 16:1713-1721, 1998.
Prabhu, N.S., Somasundaram, K., Tian, H., Enders, G.H., Satyamoorthy, K., Herlyn, M., and El-Deiry, W.S. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int. J. Oncol., 15:209-216, 1999.
Abstracts
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Weber, B.L., and El-Deiry, W.S. The BRCA1 tumor suppressor functions as a transcriptional coactivator with p53. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.

Michael J. Fisher, MD
1998 - 2000, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Children's Hospital of Philadelphia

Original Publications
Kim, K., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res., 6:335-346, 2000.
Ozoren, N., Fisher, M.J., Kim, K., Liu, C.X., Genin, A., Shifman, Y., Dicker, D.T., Spinner, N.B., Lisitsyn, N.A., and El-Deiry, W.S. Homozygous deletion of DR4 in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol., 16:917-925, 2000.
Fisher, M.J., Virmani, A. K., Wu, L., Sidransky, D., Gazdar, A.F., and El-Deiry, W.S. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clinical Cancer Research, 7:1688-1697, 2001.
Abstracts
Ozoren, N., Fisher, M., Kim, K.-H., Liu, C.-X., Lisitsyn, N.A., and El-Deiry, W.S. A homozygous deletion of the DR4 TRAIL death receptor gene is associated with TRAIL resistance of FaDu nasopharyngeal carcinoma cells. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 4601, April 1999.
Kim, K.H., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. DR4 and FLIP as major determinants of response to TRAIL in killing of normal and cancer cells. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Fisher, M.J., Virmani, A.K., Sidransky, D., Gazdar, A.F., and El-Deiry, W.S. Identification of a C626G allele in the ectodomain of TRAIL receptor DR4 and increased frequency of homozygotes in patients with lung cancer and HNSCC. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Reviews and Chapters
Fisher, M.J. and El-Deiry, W.S. Online review of “The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis” ASCO Online Journal Club, 1999. http://asco.infostreet.com/mem/oc/html/f_journal.htm

Shi-Qiong Xu, MD, PhD
1998 - 2000, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Staff scientist at Jefferson

Original Publications
Kim, K., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res., 6:335-346, 2000.
Xu, S.-Q.and El-Deiry, W.S. p21WAF1/CIP1 inhibits initiator caspase cleavage by death receptor DR4. Biochem. Biophys. Res. Comm., 269:179-190, 2000.
Abstracts
Xu, S.-Q., and El-Deiry, W.S. Apoptosis induction by adenovirus espressing DR4 lacking the TRAIL-binding domain is p53-independent. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 1121, April 1999.
Xu, S.-Q., and El-Deiry, W.S. Apoptosis induction by adenovirus expressing DR4 cytoplasmic domain is p53-independent, involves MCH5 and can be blocked by p21WAF1. American Society of Gene Therapy, 2nd Annual Meeting, June 1999, Washington D.C.
Kim, K.H., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. DR4 and FLIP as major determinants of response to TRAIL in killing of normal and cancer cells. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Xu, S-Q., Yang, W., and El-Deiry, W.S. DR4-AP/PARP10, a novel modulator of TRAIL-induced death receptor mediated apoptosis. 99th Annual AACR meeting, San Diego, CA, April, 2008.

Rishu Takimoto, MD, PhD
1998 - 2001, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Sapporo Medical University

Orginal Publications
Takimoto, R. and El-Deiry, W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene, 19:1735-1743, 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. Enhanced TRAIL sensitivity by p53 over-expression in human cancer but not normal cell lines. Int. J. Oncology, 18:241-247, 2001.
Higuchi, H., Bronk, S.F., Takikawa, Y., Werneburg, N., Takimoto, R., El-Deiry, W.S., and Gores, G.J. The bile acid glycochenodeoxycholate induces p53 independent TRAIL-receptor 2/DR5 expression and apoptosis. J. Biol. Chem., 276:38610-38618, 2001.
Wang, T., Kobayashi, T., Takimoto, R., Denes, A.E., Snuyder, E.L., El-Deiry, W.S., and Brachmann, R.K. hADA3 is required for p53 activity. EMBO J. 20:6404-6413, 2001.
Takimoto, R., Wang, W., Dicker, D.T., Rastinejad, F., Lyssikatos, J., and El-Deiry, W.S. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells, and can stabilize wild-type p53 protein. Cancer Biology and Therapy, 1:47-55, 2002.
Takimoto, R., MacLachlan, T.K., Dicker, D.T., Niitsu, Y., Mori, T., El-Deiry, W.S. BRCA1 transciptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biology and Therapy, 1:177-186, 2002.
MacLachlan, T.K., Takimoto, R. and El-Deiry, W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol., 22:4280-4292, 2002.
Wang, W., Takimoto, R., Rastinejad, F., and El-Deiry, W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15/20 or MDM2 binding. Mol. Cell. Biol., 23:2171-2181, 2003.
Abstracts
Takimoto, R., and El-Deiry, W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. p53-dependent increase in TRAIL sensitivity of human cancer cells. Gene Therapy Symposium, Caxambu, Brazil, May 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. p53 and TRAIL apoptotic signaling pathways: Novel insights for cancer gene therapy. Molecular Therapy 1(5) S16, 2000.
Takimoto, R., and El-Deiry, W.S. Identification of Damaged DNA Binding protein (DDB2) from an Affymetrix array screen as a p53 target gene and mediator of a p53-depndent DNA repair response following UV-irradiation. AACR 92nd Annual Meeting, New Orleans, LA, Abstract No. 3830, March 2001.
Takimoto, R., and El-Deiry, W.S. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells, and can stabilize wild-type p53 protein. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 4952, March 2001.
Chapters and Reviews
Takimoto, R., and El-Deiry, W.S. p53 and its targets. In Tumor Suppressing Viruses, Genes, and Drugs. Maruta, H., Ed. Academic Press, San Diego, CA, pp. 77-96, 2001.
Takimoto, R., and El-Deiry, W.S. DNA replication blockade impairs p53-transactivation. Proc. Natl. Acad. Sci. USA, 98:781-783, 2001.

Kunhong Kim, MD, PhD
1998 - 2001, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Associate Professor, Yonsei Medical University, Korea

Original Publications
Kim, K., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res., 6:335-346, 2000.
Ozoren, N., Fisher, M.J., Kim, K., Liu, C.X., Genin, A., Shifman, Y., Dicker, D.T., Spinner, N.B., Lisitsyn, N.A., and El-Deiry, W.S. Homozygous deletion of DR4 in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol., 16:917-925, 2000.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to TRAIL. Cancer Res., 60:6259-6265, 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. Enhanced TRAIL sensitivity by p53 over-expression in human cancer but not normal cell lines. Int. J. Oncology, 18:241-247, 2001.
Kim, K., Nakagawa, H., Fei, P., Rustgi, A.K., and El-Deiry, W.S. Targeting Bcl-XL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death and Diff., 11:583-587, 2004.
Kim, S-H., Kim, K., Kwagh, J.G., Dicker, D.T., Herlyn, M., Rustgi, A.K., Chen, Y., and El-Deiry, W.S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem., 279:40044-40052, 2004.
Abstracts
Ozoren, N., Fisher, M., Kim, K.-H., Liu, C.-X., Lisitsyn, N.A., and El-Deiry, W.S. A homozygous deletion of the DR4 TRAIL death receptor gene is associated with TRAIL resistance of FaDu nasopharyngeal carcinoma cells. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 4601, April 1999.
Kim, K.-H., and El-Deiry, W.S. Molecular determinants of response to TRAIL combined with chemotherapy in killing normal and cancer cells. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 3211, April 1999.
Kim, K.H., Fisher, M.J., Xu, S.-Q., and El-Deiry, W.S. DR4 and FLIP as major determinants of response to TRAIL in killing of normal and cancer cells. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Kim, K.H., and El-Deiry, W.S. Cytoplasmic and mitochondrial caspase activation triggered by TRAIL treatment in TRAIL sensitive human cancer cell lines. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. p53-dependent increase in TRAIL sensitivity of human cancer cells. Gene Therapy Symposium, Caxambu, Brazil, May 2000.
Kim, K., Takimoto, R., Dicker, D.T., Gazitt, Y., and El-Deiry, W.S. p53 and TRAIL apoptotic signaling pathways: Novel insights for cancer gene therapy. Molecular Therapy 1(5) S16, 2000.
Kim, K., Nakagawa, H., Rustgi, A., and El-Deiry, W.S. TRAIL plus a caspase 9 inhibitor induces apoptosis in human esophageal cancer but not in normal esophageal epithelial cells. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 1459, March 2001.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. Caspase 9 inhibition allows TRAIL-induced killing of cancer cells while protecting normal human liver cells. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 1713, March 2001.
Kim, S-H., Ricci, M.S., Kim, K., Nakagawa, H., Herlyn, M., Rustgi, A., and El-Deiry, W.S. Induction of apoptosis by His-tagged or native TRAIL in cultured primary human esophageal keratinocytes ot hTert, T-antigen, and c-Myc-transformed esophageal cells. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Reviews and Chapters
Wu, G.S., Kim, K.H., and El-Deiry, W.S. Involvement of the KILLER/DR5 gene in p53-dependent apoptosis and chemosensitivity. In Cancer Gene Therapy- Past Achievements and Future Challenges. Habib, N., Ed. Plenum Publishing, New York, pp. 143-161, 2000.

Timothy K. MacLachlan, PhD
1998 - 2002, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Senior Research Scientist, CuraGen Corporation, Branford, CT
2005 - Senior scientist at Genzyme
2010 - Director, Novartis Institute for Biomedical Research

Original Publications
Song, S., MacLachlan, T.K., and El-Deiry, W.S. Comparative gene expression profiling in response to p53 in a human lung cancer cell line. Biochem. Biophys. Res. Comm., 264:891-895, 1999.
Somasundaram, K., MacLachlan, T.K., Burns, T.F., Sgagias, M., Cowan, K., Weber,B.L., and El-Deiry, W.S. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene, 18:6605-6614, 1999.
MacLachlan, T.K., Somasundaram, K., Sgagias, M., Shifman, Y., Muschel, R.J., Cowan, K.H., and El-Deiry, W.S. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem., 275:2777-2785, 2000.
MacLachlan, T.K., Dash, B., Dicker, D.T., and El-Deiry, W.S. Repression of BRCA1 through a feedback loop involving p53. J. Biol. Chem., 275:31869-31875, 2000.
Takimoto, R., MacLachlan, T.K., Dicker, D.T., Niitsu, Y., Mori, T., El-Deiry, W.S. BRCA1 transciptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biology and Therapy, 1:177-186, 2002.
MacLachlan, T.K., Takimoto, R. and El-Deiry, W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol., 22:4280-4292, 2002.
MacLachlan, T.K., Takimoto, R. and El-Deiry, W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol., 22:4280-4292, 2002.
Venkataramani, R.N., MacLachlan, T.K., Chai, X., El-Deiry, W.S., and Marmorstein, R. Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. J. Biol. Chem., 277:48827-48833, 2002.
Benezra, M., Chevallier, N., Morrison, D.J., MacLachlan, T.K., El-Deiry, W.S., and Licht, J.D. BRCA1 binds to the Rel homology domain of the p65/RelA subunit of the NF-kB transcription factor. J. Biol. Chem., 278:26333-26341, 2003.
Grimberg, A., Coleman, C.M., Shi, Z., Burns, T.F., MacLachlan, T., Wang, W., and El-Deiry, W.S. Insulin-Like Growth Factor Binding Protein-2 is a Novel Mediator of p53 Inhibition of Insulin-Like Growth Factor Signaling. Cancer Biol. Ther., 5:1408-1413, 2006.
Abstracts
MacLachlan, T.K., Prabhu, N.S., Satyamoorthy, K., Herlyn, M., and El-Deiry, W.S. Human papillomavirus E6 protein downregulates the APC tumor suppressor. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 4182, April 1999.
MacLachlan, T.K., Seth, P.K., and El-Deiry, W.S. p53-independent BRCA1-regulated expression of cellular genes. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No.4586, April 1999.
MacLachlan, T.K., Somasundaram, K., Nei, T., Weber, B.L., Seth, P., and El-Deiry, W.S. Accumulation of p53 and activation of cellular genes by BRCA1. Workshop “p53: Twenty Years On,” May 1999, Trieste, Italy.
MacLachlan, T.K., and El-Deiry, W.S. Downregulation of BRCA1 through a feedback loop involving p53. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
MacLachlan, T.K., and El-Deiry, W.S. Specific control of a subset of endogenous p53 regulated genes by BRCA1. Late Breaking Abstract, AACR 92nd Annual Meeting, New Orleans, LA, March 2001.
Grimberg, A., Coleman, C., MacLachlan, T.K., Burns, T.F., and El-Deiry, W.S. Insulin-like Growth Factor Binding Protein (IGFBP)-2 is Induced by p53. The Endocrine Society's 84th Annual Meeting, 2002.
Chapters and Reviews
MacLachlan, T., Meng, R.D., and El-Deiry, W.S. “p53: 20 years on.” Report on meeting in Trieste, Italy, May 1999, J. Cell Phys. 181:371-374, 1999.
MacLachlan, T.K., and El-Deiry, W.S. Pointing (zinc) fingers at BRCA1 targets. Nature Medicine 6:1318-1319, 2000.
MacLachlan, T., and El-Deiry, W.S. BRCA1 regulation of the cell cycle and DNA damage response. In Cell Cycle Checkpoints and Cancer. Blagosklonny, M.V., Ed. Landes BioScience, Georgetown, TX, pp. 126-134, 2001.
MacLachlan, T.K., and El-Deiry, W.S. Identification of DNA binding of tumor suppressor genes by chromatin immunoprecipitation. In Tumor Suppressor Genes. Methods in Molecular Biology Series. El-Deiry, W.S., Ed. Humana Press, Totowa, NJ, 223:129-133, 2003.
MacLachlan, T.K., and El-Deiry, W.S. Analysis of cyclin-dependent kinase activity. In Tumor Suppressor Genes. Methods in Molecular Biology Series. El-Deiry, W.S., Ed. Humana Press, Totowa, NJ, 223:217-220, 2003.
MacLachlan, T., and El-Deiry, W.S. Transcriptional Activation by p53: Mechanisms and Targeted Genes, In “The p53 Tumor Suppressor Pathway and Cancer,” Zambetti, Gerard, Ed., Kluwer Academic/Plenum Publishers, in press, 2004.

Dipa Bhaumik, PhD
2001 - 03
Scientist in Campisi Lab

Paul G. Corn, MD, PhD
2000 - 04, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Instructor in Hem/Onc; K08 awarded 9/03
Assistant Professor, Department of GU Medical Oncology, MD Anderson Cancer Center

Original Publications
Corn, P.G., Summers, M.K., Fogt, F., Virmani, A.K., Gazdar, A.F., Halazonetis, T.D., and El-Deiry, W.S. Frequent hypermethylation of the 5’ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis, 24:47-51, 2003.
Corn, P.G., McDonald, E.R., III, Herman, J.G. and El-Deiry, W.S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von-Hippel-Lindau protein. Nature Genetics, 35:229-237, 2003.
Rikhof, B., Corn, P.G., and El-Deiry, W.S. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol. Ther., 2:7078-712, 2003.
Corn, P.G., Ricci, M.S., Arsham, A.M., Simon, M.C., Dicker, D.T., and El-Deiry, W.S. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biology and Therapy, 4:1285-1294, 2005.
Corn, P.G., and El-Deiry, W.S. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol. Ther., 6:1858-1866, 2007.
Abstracts
Corn, P.G., and El-Deiry, W.S. DNA damage responses of wild-type and mutant VHL-expressing renal cancer cell lines. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 2135, March 2001.
Corn, P.G., McDonald, E.R., Herman, J.G., and El-Deiry, W.S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von hippel-lindau protein. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Corn, P.G., Ricci, S., Arsham, A.M., Simon, M.C., and El-Deiry, W.S. Expression of Mxi1, a Myc antagonist, is induced by hypoxia in a HIF1alpha-dependent manner. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Corn, P.G., Ricci, M.S., Arsham, A.M., Simon, M.C., and El-Deiry, W.S. Hypoxia causes downregulation of the c-Myc signaling pathway through proteasomal degradation of c-Myc and the transcriptional upregulation of Mad1 and Mxi1, repressors of c-Myc. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Chapters and Reivews
Corn, P.G., and El-Deiry, W.S. Derangement of growth and differentiation control in oncogenesis. BioEssays, 24:83-90, 2002.

Peiwen Fei, M.D. Ph.D.
2001 - 04, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Staff scientist at NIH
2005 - Assistant professor, Mayo Clinic, MN
2010 - Associate Professor, Univ. of Hawaii, HI

Original Publications
Fei, P., Bernhard, E.J., and El-Deiry, W.S. Tissue-specific induction of p53 targets in vivo. Cancer Res., 62:7316-7327, 2002.
Burns, T.F., Fei, P., Scata, K.A., Dicker, D.T. and El-Deiry, W.S. Silencing of the novel p53 target gene, Snk/Plk2 leads to mitotic catastrophe in Paclitaxel (Taxol)-exposed cells. Mol. Cell. Biol., 23:5556-5571, 2003.
Kim, K., Nakagawa, H., Fei, P., Rustgi, A.K., and El-Deiry, W.S. Targeting Bcl-XL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death and Diff., 11:583-587, 2004.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Finnberg, N., Gruber, J.J., Fei, P., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., McKenna, W.G., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. DR5 knock-out mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol., 25:2000-13, 2005.
Abstracts
Fei, P., Wang, W., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Gruber, J.J., Fei, P., Finnberg, N., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. KILLER/DR5 knock-out mice are compromised in radiation-induced apoptosis. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Chapters and Reviews
Fei, P., and El-Deiry, W.S. p53 and Radiation Response. Oncogene, 22:5774-5783, 2003.

Bipin C. Dash, PhD
1999 - 05, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Staff Scientist, Thomas Jefferson Univ.

Original Publications
MacLachlan, T.K., Dash, B., Dicker, D.T., and El-Deiry, W.S. Repression of BRCA1 through a feedback loop involving p53. J. Biol. Chem., 275:31869-31875, 2000.
Sax, J.K., Dash, B.C., Hong, R., Dicker, D.T., and El-Deiry, W.S. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21(WAF1/CIP1) expression. Cell Cycle, 1:90-96, 2002.
Dash, B.C., and El-Deiry, W.S. G2/M-dependent phosphorylation of p21 promotes assembly and cdc2 kinase activity. Mol. Cell. Biol., 25:3364-3387, 2005.
Abstracts
Dash, B.C., Hong, R., Dicker, D., and El-Deiry, W.S. G2/M-dependent phosphorylation of p21(WAF1/CIP1) is sensitive to caffeine and a C-terminal peptide. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 1391, March 2001.
Sax, J.K., Hong, R., Dash, B.C., and El-Deiry, W.S. The CDK inhibitor butyrolactone is a potent inhibitor of p21(WAF1/CIP1) expression. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 717, March 2001.
Dash, B.C., and El-Deiry, W.S. Cell cycle dependent phosphorylation of p21:WAF1/CIP1 binds with cyclin B1 and promotes cdc2 kinase activity at M-phase. AACR 93rd Annual meeting, San Francisco, CA 2002.
Dash, B.C., and El-Deiry, W.S. Cyclin A- Cdk2 phosphorylates p21 WAF1 and phosphorylated p21 promotes assembly and cyclinB1-Cdc2 kinase activity at G2/M. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Dash, B.C., and El-Deiry, W.S. Phosphorylated p21 has a positive regulatory effect on cell cycle progression at G2/M. 2004 Meeting on The Cell Cycle, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Dash, B.C., and El-Deiry, W.S. p21 Ubiquitination by SCF-Skp2 and APC/C. AACR 96th Annual Meeting, Anaheim, California, 2005.
Chapters and Reviews
Dash, B.C., and El-Deiry, W.S. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol. Biol., 280:99-161, 2004.

M. Stacey Ricci, ScD
1999 - 05, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
FDA fellowship
2007 - Pharm/Tox Reviewer, Division of Biologic Oncology products, Office of Oncology Drug Products, Office of New Drugs, CDER, FDA

Original Publications
Mitchell, K.O., Ricci, M.S., Miyashita, T., Reed, J.C., and El-Deiry, W.S. Identification of Bax as a transcriptional target and mediator of c-Myc-induced apoptosis. Cancer Research, 60:6318-6325, 2000.
Thomas-Tikhonenko, A., Viard-Leveugle, I., Dews, M., Wehrli, P., Sevignani, C., Yu, D., Ricci, S., El-Deiry, W., Aronow, B., Kaya, G., Saurat, J.H., and French, L.E. Myc-transformed epithelial cells down-regulate Clusterin which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res., 64:3126-3136, 2004.
Ricci, M.S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D.T., and El-Deiry, W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol., 24:8541-8555, 2004.
Corn, P.G., Ricci, M.S., Arsham, A.M., Simon, M.C., Dicker, D.T., and El-Deiry, W.S. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biology and Therapy, 4:1285-1294, 2005.
Mayes, P.A., Campbell, L., Ricci, M.S., Plastaras, J.P., Dicker, D.T., and El-Deiry, W.S. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology and Therapy, 4:1068-1074, 2005.
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. (Accompanying News Feature)
Sussman, R.T., Ricci, M.S., Hart, L.S., Sun, S-Y., and El-Deiry, W.S. Chemotherapy-resistant side-population (SP) of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol. Ther., 6:1490-1495, 2007.
Abstracts
Mitchell, K.O., Ricci, M.S., Miyashita, T., Dicker, D.T., Jin, Z.-Y., Reed, J.C., and El-Deiry, W.S. Bax as a transcriptional target and mediator of c-Myc-induced apoptosis. Gordon Research Conference on Cancer, Salve Regina University, Newport, RI, August 2000.
Ricci, M.S., and El-Deiry, W.S. Identification of TC4/RAN as a novel c-Myc target gene. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 3767, March 2001.
Ricci, M.S., Sun, S-Y., El-Deiry, W.S. Myc sensitization to TRAIL-mediated apoptosis may involve upregulation of Death Receptor 4. Late Breaking Session, AACR 93rd Annual Meeting, San Francisco, CA 2002.
Kim, S-H., Ricci, M.S., Kim, K., Nakagawa, H., Herlyn, M., Rustgi, A., and El-Deiry, W.S. Induction of apoptosis by His-tagged or native TRAIL in cultured primary human esophageal keratinocytes ot hTert, T-antigen, and c-Myc-transformed esophageal cells. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Ricci, M.S., and El-Deiry, W.S. c-Myc sensitizes TRAIL-resistant cells to TRAIL by downregulating cellular FLIP expression. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Kim, S-H., Nakagawa, H., Ricci, M.S., Rustgi, A., and El-Deiry, W.S. Human esophageal tumor cells generated by Myc but not Ras or EGFR overexpression. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Corn, P.G., Ricci, S., Arsham, A.M., Simon, M.C., and El-Deiry, W.S. Expression of Mxi1, a Myc antagonist, is induced by hypoxia in a HIF1alpha-dependent manner. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Egan, C., Kim, M., Nishikawa, S., Helbing, C., Ricci, S., El-Deiry, W., Forsyth, P., Kossakowska, A., Lee, P., and Johnston, R. Increased expression of c-myc sensitizes cells to reovirus-induced oncolysis. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Corn, P.G., Ricci, M.S., Arsham, A.M., Simon, M.C., and El-Deiry, W.S. Hypoxia causes downregulation of the c-Myc signaling pathway through proteasomal degradation of c-Myc and the transcriptional upregulation of Mad1 and Mxi1, repressors of c-Myc. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Ricci, M.S., Kim, S-H., Plastaras, J., Flaherty, K., Wang, W., Smith, C. and El-Deiry, W.S. Repression of TRAIL induced c-IAP2 and Mcl-1 by c-Myc or Bay 43-9006 sensitizes Bax-deficient cells to TRAIL-induced death. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov., 2005.
Chapters and Reviews
Ricci, M.S., and El-Deiry, W.S. Novel strategies for therapeutic design in molecular oncology using gene expression profiles. Curr. Opin. Mol. Ther., 2:682-690, 2000.
Ricci, M.S., and El-Deiry, W.S. DNA footprinting. In Tumor Suppressor Genes. Methods in Molecular Biology Series. El-Deiry, W.S., Ed. Humana Press, Totowa, NJ, 223:117-127, 2003.
Ricci, M.S., and El-Deiry, W.S. The extrinsic pathway of apoptosis. In Apoptosis and Senescence in Cancer Chemotherapy and Radiotherapy. Gewirtz, Holt, and Grant, Eds. Humana Press, Totowa, NJ, pp. 31-54, 2007.
Kim, S-H., Ricci, M.S., and El-Deiry, W.S. Mcl-1: A gateway to TRAIL sensitization. Cancer Res., 68:2062-2064, 2008.

Shulin Wang, MD PhD
2000 - 05, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
2007 - Professor, Institute of Genetics, School of Life Sciences, Fudan University

Original Publications
Wang, S., and El-Deiry, W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA, 100:15095-15100, 2003.
Wang, S., and El-Deiry, W.S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-Fluorouracil. Cancer Research, 64:6666-6672, 2004.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Wang, S., and El-Deiry, W.S. p73 or p53 directly regulate human p53 transcription to maintain cell cycle checkpoints. Cancer Research, 66:6982-6989, 2006.
Wang, S., Mintz, A., Mochizuki, K., Dorsey, J.F., Ackermann, J.M., Alavi, A., and El-Deiry, W.S. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol. Ther., 10:1649-1653, 2007.
Kim, M., Liao, J., Dowling, M.L., Voong, R., Parker, S.E., Wang, S., El-Deiry, W.S., and Kao, G.D. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in Human Cancer Cells. Cancer Research, 68:3440-3449, 2008.
Abstracts
Wang, S. and El-Deiry, W.S. Mechanisms of reversal of TRAIL resistance in Bax-null human colon cancer cells. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Wang, S., and El-Deiry, W.S. Silencing of KILLER/DR5 promotes bioluminescent colon tumor xenograft growth and confers resistance to 5-FU. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Wang, S., and El-Deiry, W.S. p73 or p53 directly regulate human p53 transcription under cellular stress. AACR 96th Annual Meeting, Anaheim, California, 2005.
Mochizuki, K., Liu, Y.Y., Wang, S., Kim, C., Gewirtz, D., Alavi, A., and El-Deiry, W.S. 3-Dimensional bioluminescent imaging of tumor xenografts. AACR 96th Annual Meeting, Anaheim, California, 2005.
Chapters and Reviews
Wang, S., and El-Deiry, W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628-8633, 2003.
Wang, S., and El-Deiry, W.S. Cytochrome c: A Crosslink between the Mitochondria and the Endoplasmic Reticulum in Calcium-Dependent Apoptosis. Cancer Biol. Ther., 3:44-46, 2004.
Wang, S., and El-Deiry, W.S. The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat. Res., 119:175-187, 2004.

John Plastaras, MD PhD
2004 - 06, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Radiation Oncology Resident, Holman Pathway, U. Penn
2007 - Instructor in Radiation Oncology, U. Penn
2008 - Assistant Professor, Radiation Oncology, U. Penn

Original Publications
Mayes, P.A., Campbell, L., Ricci, M.S., Plastaras, J.P., Dicker, D.T., and El-Deiry, W.S. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology and Therapy, 4:1068-1074, 2005.
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. (Accompanying News Feature)
Plastaras, J.P., Kim, S-H., Liu, Y., Dicker, D.T., Dorsey, J.F., McDonough, J., Cerniglia, G., Rajendran, R., Gupta, A., Rustgi, A.K., Diehl, J.A., Smith, C., Flaherty, K., and El-Deiry, W.S. Cell cycle and schedule dependent anti-tumor effects of Sorafenib combined with radiation. Cancer Res., 67:9443-9454, 2007.
Plastaras, J.P., Dorsey, J.F., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol. Ther. 7:2047-2053, 2008.
Dorsey, J.F., Mintz, A., Tian, X., Dowling, M.L., Plastaras, J.P., Dicker, D.T., Kao, G.D., and El-Deiry, W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther., 8:3285-3295, 2009.
Abstracts
Plastaras, J.P., and El-Deiry, W.S. Role of insulin-induced Akt activation in TRAIL-induced apoptosis. AACR 96th Annual Meeting, Anaheim, California, 2005.
Ricci, M.S., Kim, S-H., Plastaras, J., Flaherty, K., Wang, W., Smith, C. and El-Deiry, W.S. Repression of TRAIL induced c-IAP2 and Mcl-1 by c-Myc or Bay 43-9006 sensitizes Bax-deficient cells to TRAIL-induced death. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov., 2005.
Plastaras, J.P., Soto, N.M., Dicker, D.T., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Sorafenib (BAY 43-9006) slows cell cycle progression, is a TRAIL sensitizer, but is not a radiosensitizer. 97th Annual AACR meeting, Washington, D.C., April 2006.
Dorsey, J.F., Plastaras, J.P., and El-Deiry, W.S. p53-regulated transcriptional response to radiation in the cerebral cortex. 48th Annual ASTRO Meeting, Philadelphia, PA, November, 2006.
Plastaras, J.P., Dorsey, J.P., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. 48th Annual ASTRO Meeting, Philadelphia, PA, November, 2006.

Laura Rozan, PhD
2003 - 06, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Senior Consultant at Navigant Consulting
2012 - Account Director, Oncology Franchise, ImpactRx

Original Publications
Rozan, L.M., and El-Deiry, W.S. Identification and Characterization of Proteins Interacting with Traf4, an Enigmatic p53 Target. Cancer Biol. Ther., 5:1228-1235, 2006.
Yang, W-S., Rozan, L.M., McDonald, E.R., III, Matthew, E., Wang, W., Dicker, D.T., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARPs) 1/2 are novel ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem., 282:3273-3281, 2007.
Abstracts
Rozan, L., and El-Deiry, W.S. Functional characterization of Traf4, a p53 transcriptional target. AACR 96th Annual Meeting, Anaheim, California, 2005.
Yang, W-S., Rozan, L., Wang, W., Matthew, E., Dicker, D.T., and El-Deiry, W.S. CARPs negatively regulate levels of phosphorylated p53. 97th Annual AACR meeting, Washington, D.C., April 2006.
Chapters and Reviews
Rozan, L.M., and El-Deiry, W.S. p53 downstream target genes and tumor suppression: A classical view in evolution. Cell Death Diff., 14:3-9, 2007.

Kazuhiro Ogi, MD PhD
2005 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Faculty at Sapporo Medical University

Original Publications
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. (Accompanying News Feature)
Abstracts
Kazuhiro, O., and El-Deiry, W.S. Silencing of the NFkB p65 subunit inhibits HIF1-alpha expression during hypoxia and sensitizes HCT116 colon cancer cells to CPT11 but not TRAIL. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.

Akiva Mintz, MD PhD
2005 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Nuclear Medicine Fellowship at Penn
2008 - Assistant Professor, Wake Forest University
Director, Brain Tumor Center of Excellence, Wake Forest University
Section Head, Division of Radiological Science, Wake Forest University

Original Publications
Wang, S., Mintz, A., Mochizuki, K., Dorsey, J.F., Ackermann, J.M., Alavi, A., and El-Deiry, W.S. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol. Ther., 10:1649-1653, 2007.
Dorsey, J.F., Mintz, A., Tian, X., Dowling, M.L., Plastaras, J.P., Dicker, D.T., Kao, G.D., and El-Deiry, W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther., 8:3285-3295, 2009.
Abstracts
Mintz, A., Alavi, A., and El-Deiry, W.S. Retargeted cytokine-immunoglobulin chimeric fusion proteins to target IL13Ra2(+) tumors. 97th Annual AACR meeting, Washington, D.C., April 2006.
Dorsey, J.F., Mintz, A., and El-Deiry, W.S. Targeted therapy of glioblastoma multiforme with paclitaxel and TNF-related apoptosis-inducing-ligand (TRAIL): a synergistic chemotherapeutic-biologic approach. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Mintz, A., Dorsey, J.F., Alavi, A., and El-Deiry, W.S. Multimodality in vivo imaging of viability and death in response to Apo2L/TRAIL therapy. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.

Jay Dorsey, MD PhD
2005 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Radiation Oncology Residency at Penn
2008 - Assistant Professor, Radiation Oncology, U. Penn

Original Publications
Plastaras, J.P., Kim, S-H., Liu, Y., Dicker, D.T., Dorsey, J.F., McDonough, J., Cerniglia, G., Rajendran, R., Gupta, A., Rustgi, A.K., Diehl, J.A., Smith, C., Flaherty, K., and El-Deiry, W.S. Cell cycle and schedule dependent anti-tumor effects of Sorafenib combined with radiation. Cancer Res., 67:9443-9454, 2007.
Matthew, E.M., Yen, T.J., Dicker, D.T., Dorsey, J.F., Yang, W., Navaraj, A., and El-Deiry, W.S. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle, 6:2571-2578, 2007.
Wang, S., Mintz, A., Mochizuki, K., Dorsey, J.F., Ackermann, J.M., Alavi, A., and El-Deiry, W.S. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol. Ther., 10:1649-1653, 2007.
Plastaras, J.P., Dorsey, J.F., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol. Ther. 7:2047-2053, 2008.
Dorsey, J.F., Mintz, A., Tian, X., Dowling, M.L., Plastaras, J.P., Dicker, D.T., Kao, G.D., and El-Deiry, W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther., 8:3285-3295, 2009.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Abstracts
Dorsey, J.F., and El-Deiry, W.S. Role of p53 in TRAIL-induced apoptosis in glioblastoma multiforme and modulation by taxol, rapamycin or temozolomide. 97th Annual AACR meeting, Washington, D.C., April 2006.
Dorsey, J., and El-Deiry, W.S. Combination Taxol-TRAIL therapy for Glioblastoma Multiforme with mutant p53 gene. ASCI Meeting, Chicago, IL, April 2006.
Dorsey, J.F., Plastaras, J.P., and El-Deiry, W.S. p53-regulated transcriptional response to radiation in the cerebral cortex. 48th Annual ASTRO Meeting, Philadelphia, PA, November, 2006.
Plastaras, J.P., Dorsey, J.P., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. 48th Annual ASTRO Meeting, Philadelphia, PA, November, 2006.
Dorsey, J.F., and El-Deiry, W.S. Synergistic activity of taxol and TRAIL targets glioblastoma multiforme with mutant p53. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2006.
Dorsey, J.F., Mintz, A., and El-Deiry, W.S. Targeted therapy of glioblastoma multiforme with paclitaxel and TNF-related apoptosis-inducing-ligand (TRAIL): a synergistic chemotherapeutic-biologic approach. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Mintz, A., Dorsey, J.F., Alavi, A., and El-Deiry, W.S. Multimodality in vivo imaging of viability and death in response to Apo2L/TRAIL therapy. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Mayes, P.A., Liu, J.J., Kuribayashi, K., Jee, D.I.H., Dorsey, J.F., Dicker, D.T., Brown, J.M., Furth, E.E., and El-Deiry, W.S. Overcoming drug resistance of hypoxic cancer cells and tumors via stabilization of c-Myc protein through inhibition of GSK3. 99th Annual AACR meeting, San Diego, CA, April, 2008.

Paul C. Tumeh, MD
2006 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Radiation Oncology Residency at Penn

Orginal Publications
Tumeh, P.C., Lerner, J.M., Dicker, D.T., and El-Deiry, W.S. Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: Implications for monitoring angiogenesis. Cancer Biol. Ther., 6:447-453, 2007.

Seok-Hyun Kim, MD PhD
2001 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Faculty Investigator Position at National Cancer Center, Korea

Orginal Publications
Kim, S-H., Kim, K., Kwagh, J.G., Dicker, D.T., Herlyn, M., Rustgi, A.K., Chen, Y., and El-Deiry, W.S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem., 279:40044-40052, 2004.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Dicker, D.T., Kim, S-H., Jin, Z., and El-Deiry, W.S. Heterogeneity in Non-Invasive Detection of Apoptosis Among Human Tumor Cell Lines Using Annexin-V Tagged with EGFP or Qdot-705. Cancer Biol. Ther., 4:1014-1017, 2005.
Finnberg, N., Kim, S-H., Furth, E.E., Liu, J.J., Russo, P., Piccoli, D.A., Grimberg, A., and El-Deiry, W.S. Noninvasive Fluorescence Imaging of Cell Death in Fresh Human Colon Epithelia Treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol. Ther., 4:937-942, 2005.
Kim, S-H., Nakagawa, H., Navaraj, A., Naomoto, Y., Klein-Szanto, A.J.P., Rustgi, A.K., and El-Deiry, W.S. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Research, 66:10415-10424, 2006. Featured on the Cover; November 1, 2006
Oyama, K., Okawa, T., Nakagawa, H., Takaoka, M., Andl, C.D., Kim, S-H., Klein-Szanto, A., Herlyn, M., El-Deiry, W., and Rustgi, A.K. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene, 26:2353-2364, 2007.
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. Accompanying News Feature
Takaoka, M., Kim, S-H., Okawa, T., Michaylira, C.Z., Stairs, D., Johnstone, C.N., Andl, C.D., Rhoads, B., Lee, J., Klein-Szanto, A.J.P., El-Deiry, W.S., and Nakagawa, H. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol. Ther., 6:534-540, 2007.
Plastaras, J.P., Kim, S-H., Liu, Y., Dicker, D.T., Dorsey, J.F., McDonough, J., Cerniglia, G., Rajendran, R., Gupta, A., Rustgi, A.K., Diehl, J.A., Smith, C., Flaherty, K., and El-Deiry, W.S. Cell cycle and schedule dependent anti-tumor effects of Sorafenib combined with radiation. Cancer Res., 67:9443-9454, 2007.
Plastaras, J.P., Dorsey, J.F., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol. Ther. 7:2047-2053, 2008.
Abstracts
Kim, S-H., Ricci, M.S., Kim, K., Nakagawa, H., Herlyn, M., Rustgi, A., and El-Deiry, W.S. Induction of apoptosis by His-tagged or native TRAIL in cultured primary human esophageal keratinocytes ot hTert, T-antigen, and c-Myc-transformed esophageal cells. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Kim, S-H., Nakagawa, H., Ricci, M.S., Rustgi, A., and El-Deiry, W.S. Human esophageal tumor cells generated by Myc but not Ras or EGFR overexpression. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Kim, S-H., and El-Deiry, W.S. Proteasomal degradation of SV40 T-antigen after exposure to DNA damaging agents or c-Myc overexpression: A potential obstacle to efficient human cell transformation. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Kim, S-H., Nakagawa, H., Rustgi, A., and El-Deiry, W.S. In vivo bioluminescence imaging of tumor formation following EGFR, Akt or Ras overexpression in immortalized primary human esophageal epithelial cells. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Ricci, M.S., Kim, S-H., Plastaras, J., Flaherty, K., Wang, W., Smith, C. and El-Deiry, W.S. Repression of TRAIL induced c-IAP2 and Mcl-1 by c-Myc or Bay 43-9006 sensitizes Bax-deficient cells to TRAIL-induced death. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov., 2005.
Kim, S-H., Rustgi, A.K., and El-Deiry, W.S. p53 protein acts as an obstacle for human cell transformation by the SV40 early region due to proteasomal degradation of Large T antigen. 97th Annual AACR meeting, Washington, D.C., April 2006.
Wang, W., Kim, S-H., Dicker, D.T., and El-Deiry, W.S. RbBP5 differentially regulates TRAIL and adriamycin-induced apoptosis in tumor cells. 97th Annual AACR meeting, Washington, D.C., April 2006.
Plastaras, J.P., Dorsey, J.P., Carroll, K., Kim, S-H., Birnbaum, M.J., and El-Deiry, W.S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. 48th Annual ASTRO Meeting, Philadelphia, PA, November, 2006.
Kuribayashi, K., Mayes, P.A., Kim, S-H., Rustgi, A.K., and El-Deiry, W.S. High-throughput bioluminescence screening for small molecules that overcome chemo- and TRAIL-resistance in human esophageal cancer cell lines. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Takaoka, M., Kim, S-H., Michaylira, C.Z., Stairs, D., Okawa, T., Andl, C.D., Johnstone, C.N., Rhoades, B., Lee, J., Klein-Szanto, A.J.P., El-Deiry, W.S., and Nakagawa, H. Insulin-like growth factor binding protein-3 regulates esophageal tumor formation and growth through insulin-like growth factor-dependent and independent mechanisms. Digestive Disease Week and the 108th annual meeting of the American Gastroenterological Association, Washington DC, May 19-24, 2007.
Chapters and Reviews
Kim, S-H., Ricci, M.S., and El-Deiry, W.S. Mcl-1: A gateway to TRAIL sensitization. Cancer Res., 68:2062-2064, 2008.

Kageaki Kuribayashi, MD PhD
2005 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Faculty position at Sapporo Medical University

Original Publications
Kuribayashi, K., Krigsfeld, G., Wang, W., Xu, J., Mayes, P.A., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7:2034-2038, 2008.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Kuribayashi, K., Finnberg, N., Jeffers, J.R., Zambetti, G.P., and El-Deiry, W.S. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle, 10:2380-2389, 2011.
Abstracts
Kuribayashi, K., Rustgi, A.K., and El-Deiry, W.S. Determinants of chemo- and TRAIL sensitivity in esophageal cancer cell lines. 3rd International Conference on Tumor Progression and Therapeutic Resistance, Baltimore, MD, October, 2006.
Kuribayashi, K., Mayes, P.A., Kim, S-H., Rustgi, A.K., and El-Deiry, W.S. High-throughput bioluminescence screening for small molecules that overcome chemo- and TRAIL-resistance in human esophageal cancer cell lines. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Mayes, P.A., Liu, J.J., Kuribayashi, K., Jee, D.I.H., Dorsey, J.F., Dicker, D.T., Brown, J.M., Furth, E.E., and El-Deiry, W.S. Overcoming drug resistance of hypoxic cancer cells and tumors via stabilization of c-Myc protein through inhibition of GSK3. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Chapters and Reviews
Kuribayashi, K., Mayes, P.A., and El-Deiry, W.S. What are Caspases 3 and 7 Doing Upstream of the Mitochondria? Cancer Biol. Ther. 5:763-765, 2006.
Kuribayashi, K., and El-Deiry, W.S. Regulation of programmed cell death by the p53 pathway. Adv. Exp. Med. Biol. 615:201-221, 2008.

Kimberly Scata, Ph.D
2002 - 07, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Scientific Managing Editor, Cancer Biology and Therapy, Landes BioScience
Staff Scientist, Penn State University

Original Publications
Burns, T.F., Fei, P., Scata, K.A., Dicker, D.T. and El-Deiry, W.S. Silencing of the novel p53 target gene, Snk/Plk2 leads to mitotic catastrophe in Paclitaxel (Taxol)-exposed cells. Mol. Cell. Biol., 23:5556-5571, 2003.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Scata, K.A., and El-Deiry, W.S. BRCA1-mediated repression of p53 proapoptotic targets. AACR 96th Annual Meeting, Anaheim, California, 2005.
Scata, K.A., and El-Deiry, W.S. BRCA1 regulation of p53 stability and target expression. 97th Annual AACR meeting, Washington, D.C., April 2006.
Scata, K.A., and El-Deiry, W.S. BRCA1 regulation of p53 stability and target selectivity. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Scata, K.A., and El-Deiry, W.S. The DNp73 isoform provides novel insights into the regulation of p53 by BRCA1 to favor cell survival over cell death. 101st Annual AACR meeting, Washington, D.C., April 2010.
Scata, K.A., and El-Deiry, W.S. BRCA1 regulates p53 target expression via DNp73. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Scata, K.A., and El-Deiry, W.S. Managing the cross talk: BRCA1 and its regulation of the p53 family, E2f1/Rb and apoptosis. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Chapters and Reviews
Scata, K.A., and El-Deiry, W.S. Zebrafish: Swimming towards a role for Fanconi genes in DNA repair. Cancer Biol. Ther., 3:501-502, 2004.
Scata, K.A., and El-Deiry, W.S. Taming NEMO to Slay Cancer Cells. Cancer Biol. Ther., 5:1096-1097, 2006.
Scata, K.A., and El-Deiry, W.S. p53, BRCA1 and breast cancer chemoresistance. In Breast Cancer Chemosensitivity, Dihua Yu and Mien-Chie Hung, Eds., Advances in Experimental Medicine and Biology, 608:70-86, 2007.

Joe Ackerman, PhD
2005 - 08, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Associate Manager, Business Integration, Merck
2008 - Associate Director, Merck Research Labs, Financial Planning & Analysis at Merck

Orginial Publications
Wang, S., Mintz, A., Mochizuki, K., Dorsey, J.F., Ackermann, J.M., Alavi, A., and El-Deiry, W.S. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol. Ther., 10:1649-1653, 2007.
Abstracts
Ackermann, J.M., Halazonetis, T.D., and El-Deiry, W.S. Distinct pathways of upstream activation of p53 during hypoxia versus desferioxamine exposure. 97th Annual AACR meeting, Washington, D.C., April 2006.
Ackermann, J.M., and El-Deiry, W.S. Stabilization of p53 by nutlin-3 promotes the selection of cells with non-functional p53. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Chapters and Reviews
Ackermann, J.M., and El-Deiry, W.S. Targeting ATM/ATR in the DNA damage checkpoint. In Checkpoint Responses and Cancer Therapy, Dai, W., Ed., Humana Press, pp. 93-116, 2008.

Xiaobing Tian, PhD
2006 - 08, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Research Fellow, Penn Radiation Oncology

Orginial Publications
Dorsey, J.F., Mintz, A., Tian, X., Dowling, M.L., Plastaras, J.P., Dicker, D.T., Kao, G.D., and El-Deiry, W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther., 8:3285-3295, 2009.
Abstracts
Tian, X., Yang, W., Navaraj, A., and El-Deiry, W.S. Molecular imaging of p53 mRNA. 99th Annual AACR meeting, San Diego, CA, April, 2008.

Arunasalam Navaraj, PhD
2003 - 08, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Post-doctoral Scientist, India

Orginial Publications
Navaraj, A., Mori, T., and El-Deiry, W.S. Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol. Ther., 4:1409-1414, 2005.
Kim, S-H., Nakagawa, H., Navaraj, A., Naomoto, Y., Klein-Szanto, A.J.P., Rustgi, A.K., and El-Deiry, W.S. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Research, 66:10415-10424, 2006. (Featured on the Cover; November 1, 2006)
Matthew, E.M., Yen, T.J., Dicker, D.T., Dorsey, J.F., Yang, W., Navaraj, A., and El-Deiry, W.S. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle, 6:2571-2578, 2007.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., Dicker, D.T., Henske, E.P., and El-Deiry, W.S. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle, 8:4168-4175, 2009.
Navaraj, A., Finnberg, N., Dicker, D.T., Yang, W., Matthew, E.M., and El-Deiry, W.S. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol. Ther., 8:2417-2444, 2009.
Wang, W., Gallant, J-N., Katz, S.I., Dolloff, N.G., Smith, C.D., Abdulghani, J., Allen, J.E., Dicker, D.T., Hong, B., Navaraj, A., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther., 12:229-238, 2011.
Gallant, J-N., Allen, J.E., Smith, C.D., Dicker, D.T., Wang, W., Dolloff, N.G., Navaraj, A., and El-Deiry, W.S. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther., 12:239-251, 2011.
Abstracts
Navaraj, A., and El-Deiry, W.S. Cooperation between p53 and BRCA1 in repair of cyclobutane pyrimidine dimers but not (6-4) photoproducts following UV exposure of human breast cancer cells. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Arunasalam, N., and El-Deiry, W.S. Transformation of DNA repair-deficient fibroblasts and mammary epithelial cells with or without BRCA1 knockdown. AACR 96th Annual Meeting, Anaheim, California, 2005.
Navaraj, A., Dicker, D.T., and El-Deiry, W.S. Transformation of DNA repair-deficient XPC fibroblasts and mammary epithelial cells with BRCA1 siRNA knockdown. 97th Annual AACR meeting, Washington, D.C., April 2006.
Navaraj, A., and El-Deiry, W.S. Enhanced H-Ras-mediated transformation of human mammary epithelial cells following BRCA1 knockdown is associated with elevated cyclin D1, c-myc and ER-alpha. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Tian, X., Yang, W., Navaraj, A., and El-Deiry, W.S. Molecular imaging of p53 mRNA. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Navaraj, A., and El-Deiry, W.S. Characterization of EMT and in vivo bio-imaging of transformed mammary epithelial cells with H-Ras over-expression and BRCA1 siRNA knockdown. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., and El-Deiry, W.S. The role of DNA damage-inducible Polo-like kinase 2 as a tumor suppressor and target for therapy. 100th Annual AACR meeting, Denver, CO, April 2009.
Finnberg, N.K., Lang, K., Arunasalam, N., Motoyama, N., Zhou, B-B., and El-Deiry, W.S. Chk2 triggers expression of XIAP in the murine colonic epithelium following treatment with 5-FU but not CPT-11. 100th Annual AACR meeting, Denver, CO, April 2009.
Finnberg, N.K., Arunasalam, N., Lang, K., Cerniglia, G., Motoyama, N., Zhou, B-B., and El-Deiry, W. Targeting of DR5/TRAIL-R2 in combination with irinotecan triggers p53- and chk2-dependent gastrointestinal toxicity in mice in vivo and synergistic cell death in human gastrointestinal epithelial cells in vitro. 101st Annual AACR meeting, Washington, D.C., April 2010.
Finnberg, N.K., Arunasalam, N., Lang, K., Cerniglia, G., Motoyama, N., Zhou, B-B., and El-Deiry, W.S. Chk2-inhibition promotes increased killing of human colorectal cancer cells and protects from gastrointestinal toxicity following irinotecan/TRAIL death receptor agonists (TDRA). 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Navaraj, A., Dicker, D.T., Dolloff, N., and El-Deiry, W.S. Multiplexed detection of phospho-ERK as a marker of H-Ras signaling, EGFR and cancer stem cell marker expression in breast cancer cells recovered from human blood. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Navaraj, A., Dicker, D.T., and El-Deiry, W.S. Mouse models for detection of circulating tumor cells from breast cancer. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Prabhu, V.V., Hong, B., Allen, J.E., Dicker, D.T., Navaraj1 A., Kopelovich, L., and El-Deiry, W.S. Anti-tumor effects of the p53-pathway restoring compound Prodigiosin in colorectal Cancer involve effects on apoptotic signaling, angiogenesis and cancer stem cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Dolloff, N.G., Zhou, L., Peters, K., Navaraj, A., Allen, J.E., Das, A., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Navaraj, A., Nguyen, K., Lim, B., Dicker, D.T., and El-Deiry, W.S. Drug screening for small molecules targeting BRCA1-deficient cells. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Faltas, B., Zeidan, A., Peters, K., Das, A., Joudeh, J., Navaraj, A., Dolloff, N.G., Harvey, H.A., Jiang, Y., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J. Clin. Oncol., 29:2947-2948, 2011.

Elizabeth Matthew, PhD
2003 - 08, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Post-doctoral Scientist
Staff Scientist, Penn State University

Original Publications
Yang, W-S., Rozan, L.M., McDonald, E.R., III, Matthew, E., Wang, W., Dicker, D.T., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARPs) 1/2 are novel ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem., 282:3273-3281, 2007.
Matthew, E.M., Yen, T.J., Dicker, D.T., Dorsey, J.F., Yang, W., Navaraj, A., and El-Deiry, W.S. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle, 6:2571-2578, 2007.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., Dicker, D.T., Henske, E.P., and El-Deiry, W.S. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle, 8:4168-4175, 2009.
Navaraj, A., Finnberg, N., Dicker, D.T., Yang, W., Matthew, E.M., and El-Deiry, W.S. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol. Ther., 8:2417-2444, 2009.
Abstracts
Matthew, E., and El-Deiry, W.S. Localization of the p53 target Polo-like kinase 2 to centrosome-like cytoplasmic structures. AACR 96th Annual Meeting, Anaheim, California, 2005.
Yang, W-S., Rozan, L., Wang, W., Matthew, E., Dicker, D.T., and El-Deiry, W.S. CARPs negatively regulate levels of phosphorylated p53. 97th Annual AACR meeting, Washington, D.C., April 2006.
Finnberg, N.K., Matthew, E., Bernhard, E., Klein-Szanto, A., and El-Deiry, W.S. Decreased survival, chronic inflammation and tumor susceptibility of irradiated DR5-null mice. 97th Annual AACR meeting, Washington, D.C., April 2006.
Matthew, E., and El-Deiry, W.S. Replication stress, defective S-phase checkpoint and increased cell death in Plk2-deficient human cancer cells. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Matthew, E.M., Liu, Y.Y., Dicker, D.T., and El-Deiry, W.S. Potential role of Polo-like kinase 2 in tumor suppression and resistance to CPT-11. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., and El-Deiry, W.S. The role of DNA damage-inducible Polo-like kinase 2 as a tumor suppressor and target for therapy. 100th Annual AACR meeting, Denver, CO, April 2009.
Matthew, E.M., Zhou, L., Yang, Z., Lamparella, N., Liu, Y.Y., and El-Deiry, W.S. A Multiplexed Marker-based Algorithm for Diagnosis of Carcinoma of Unknown Primary (CUP) Using Circulating Tumor Cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Matthew, E.M., Yang, Z., El-Deiry, W.S. Plk2 Loss and mTOR Signaling in Advanced Colorectal Cancer. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Sheikh, H., Matthew, E., and El-Deiry, W.S. Development of gamma-H2AX assay to assess toxicity and efficacy from chemotherapy in circulating tumor cells (CTCs) and peripheral blood lymphocytes. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Matthew, E.M., Gallant, J-N., Zhou, L., Yang, Z., Drabick, J.J., Truica, C.I., Lamparella, N.E., Dicker, D.T., and El-Deiry, W.S. Isolation, culture and immunophenotyping of live patient-derived circulating tumor cells. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.

Wensheng Yang, PhD
2003 - 09, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Research Scientist, Dept. of Radiation Oncology, U. Penn

Original Publications
Yang, W-S., Rozan, L.M., McDonald, E.R., III, Matthew, E., Wang, W., Dicker, D.T., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARPs) 1/2 are novel ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem., 282:3273-3281, 2007.
Matthew, E.M., Yen, T.J., Dicker, D.T., Dorsey, J.F., Yang, W., Navaraj, A., and El-Deiry, W.S. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle, 6:2571-2578, 2007.
Yang, W., Dicker. D.T., Chen, J., and El-Deiry, W.S. CARPs enhance p53 turnover by degrading 14-3-3 and stabilizing MDM2. Cell Cycle, 7:670-682, 2008.
Liao, W., Xiao, Q., Tchikov, V., Fujita, K., Yang, W., Wincovitch, S., Garfield, S., Conze, D., El-Deiry, W.S., Schutze, S., and Srinivasula, S.M. CARP-2 is an endosome-associated ubiquitin protein ligase for RIP and regulates TNF-induced NF-kB activation. Current Biology, 6:641-649, 2008.
Liao, W., Fujita, K.I., Xiao, Q., Tchikov, V., Yang, W., Gunsor, M., Garfield, S., Goldsmith, P., El-Deiry, W.S., Schutze, S., and Srinivasula, S.M. CARP1 regulates induction of NF-kappaB by TNFalpha. Curr. Biol. 19:R17-R19, 2009.
Navaraj, A., Finnberg, N., Dicker, D.T., Yang, W., Matthew, E.M., and El-Deiry, W.S. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol. Ther., 8:2417-2444, 2009.
Abstracts
Yang, W-S., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARP) 1/2 are novel E3 ligases for p53. AACR 96th Annual Meeting, Anaheim, California, 2005.
Yang, W-S., Rozan, L., Wang, W., Matthew, E., Dicker, D.T., and El-Deiry, W.S. CARPs negatively regulate levels of phosphorylated p53. 97th Annual AACR meeting, Washington, D.C., April 2006.
Yang, W., and El-Deiry, W.S. CARP1/2 synergize with Mdm2 to regulate p53. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Yang, W., Chen, J., and El-Deiry, W.S. Novel pathway of MDM2 stabilization by CARP2 that involves 14-3-3 degradation. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Tian, X., Yang, W., Navaraj, A., and El-Deiry, W.S. Molecular imaging of p53 mRNA. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Xu, S-Q., Yang, W., and El-Deiry, W.S. DR4-AP/PARP10, a novel modulator of TRAIL-induced death receptor mediated apoptosis. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Chapters and Reviews
Yang, W., and El-Deiry, W.S. CARPs are E3 ligases that target apical caspases and p53. Cancer Biol. Ther., 6:1676-1683, 2007.
Yang, W. Dolloff, N.G., and El-Deiry, W.S. ERK and MDM2 prey on FOXO3a. Nature Cell Biol., 10:125-126, 2008.

Lori S. Hart, PhD
2006 - 10, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Research Associate, Dept. of Radiation Oncology, U. Penn
2012 - Scientist in John Maris' Group, Children's Hospital of Philadelphia

Original Publications
Sussman, R.T., Ricci, M.S., Hart, L.S., Sun, S-Y., and El-Deiry, W.S. Chemotherapy-resistant side-population (SP) of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol. Ther., 6:1490-1495, 2007.
Tavaluc, R.T., Hart, L.S., Dicker, D.T., and El-Deiry, W.S. Effects of low confluency, serum starvation, and hypoxia on the side population of cancer cell lines, Cell Cycle, 6:2554-2562, 2007.
Huang, C., Zhang, X.M., Tavaluc, R.T., Hart, L.S., Dicker, D.T., Wang, W., and El-Deiry, W.S. The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol. Ther. 8:2184-2191, 2009.
Allen, J.E., Hart, L.S., Dicker, D.T., Wang, W., and El-Deiry, W.S. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol. Ther. 8:2192-2203, 2009.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., Dicker, D.T., Henske, E.P., and El-Deiry, W.S. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle, 8:4168-4175, 2009.
Hart, L.S., Dolloff, N.G., Dicker, D.T., Koumenis, C., Christensen, J.G., Grimberg, A., and El-Deiry, W.S. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle, 10:2331-2338, 2011.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Dolloff, N.G., Mayes, P.A., Hart, L.S., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Off-target Lapatinib activity derives from TRAIL death receptor up-regulation. Science Translational Medicine, 3:92-102, 2011.
Finnberg, N.K., Hart, L.S., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. American J. Pathol., 179:2169-2176, 2011.
Abstracts
Hart, L.S., Dicker, D.T., Grimberg, A., and El-Deiry, W.S. IGF-1 enriches the side population of colon and breast cancer cell lines. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Hart, L.S., Dicker, D.T., Fels, D.R., Koumenis, C., and El-Deiry, W.S. Proteasome inhibition: Preferentially targeting the putative cancer stem cell. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., and El-Deiry, W.S. The role of DNA damage-inducible Polo-like kinase 2 as a tumor suppressor and target for therapy. 100th Annual AACR meeting, Denver, CO, April 2009.
Dolloff, N.G., Hart, L.S., Mayes, P.A., and El-Deiry, W.S. Dual GSK-3/CDK inhibitors induce multiple myeloma cell death and eliminate putative cancer stem cell populations. 101st Annual AACR meeting, Washington, D.C., April 2010.
Dolloff, N.G., Hart, L.S., Mayes, P.A., Dicker, D.T., Humphreys, R.C., Gilmer, T.M., and El-Deiry, W.S. Novel anti-tumor activity of lapatinib derives from off-target up-regulation of TRAIL death receptors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Hart, L.S., Finnberg, N., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., Thomas-Tikhonenko, A., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Hart, L.S., Dicker, D.T., Grimberg, A., Christensen, J., and El-Deiry, W.S. The fully human IGF-1 receptor antibody, CP-751,871, targets putative colon cancer stem cell populations. 101st Annual AACR meeting, Washington, D.C., April 2010.
Dolloff, N.G., Mayes, P., Hart, L., Dicker, D., and El-Deiry, W.S. Off-target lapatinib activity upregulates TRAIL death receptors in colon cancer cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Chapters and Reviews
Hart, L.S., and El-Deiry, W.S. Invincible, but not invisible: Imaging approaches toward in vivo detection of cancer stem cells. J. Clin. Oncol., 26:2901-2910, 2008.
Hart, L.S., and El-Deiry, W.S. Cell death: a new Par-4 the TRAIL. Cell 138:220-222, 2009.

Fang Chen, PhD
2009 - 10, technical specialist, El-Deiry Lab, University of Pennsylvania
Technical Specialist, Microarray Facility, U. Penn

Abstracts
Hong, B., Chen, F., Dicker, D.T., and El-Deiry, W.S. Restoration of p53 pathway signaling and apoptotic induction by prodigiosin and its structurally-related compound (NSC247562) in p53-deficient human colon carcinoma cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Chapters and Reviews
Chen, F., Wang, W., and El-Deiry, W.S. Current strategies to target p53 in cancer. Biochemical Pharmacology, 80:724-730, 2010.

Wenge Wang, MD, PhD
2001 - 10, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Internal Medicine Residency
Hematology/Oncology Fellowship, Penn State University

Original Publications
Takimoto, R., Wang, W., Dicker, D.T., Rastinejad, F., Lyssikatos, J., and El-Deiry, W.S. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells, and can stabilize wild-type p53 protein. Cancer Biology and Therapy, 1:47-55, 2002.
Wang, W., Takimoto, R., Rastinejad, F., and El-Deiry, W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15/20 or MDM2 binding. Mol. Cell. Biol., 23:2171-2181, 2003.
Wang, W. and El-Deiry, W.S. Bioluminescent Molecular Imaging of Endogenous and Exogenous p53-Mediated Transcription in vitro and in vivo using an HCT116 Human Colon Carcinoma Xenograft Model. Cancer Biol. Ther., 2:196-202, 2003.
Gruber, P.J., Li, Z., Li, H., Worrad, D., Huang, B., Abdullah, I., Wang, W., El-Deiry, W., Ferrari, V.A., Zhou, R. In vivo imaging of MLC2v-luciferase, a cardiac-specific reporter gene expression in mice. Acad. Radiol., 11:1022-1028, 2004.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Wang, W., Ho, W.C., Dicker, D.T., MacKinnon, C., Winkler, J.D., Marmorstein, R., and El-Deiry, W.S. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol. Ther., 4:893-898, 2005.
Liu, J.J., Wang, W., Dicker, D.T., and El-Deiry, W.S. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol. Ther., 4:885-892, 2005.
Tang, J., Qu, L., Zhang, J., Wang, W., Michaelson, J.S., El-Deiry, W.S., and Yang, X. Daxx promotes the stability of Mdm2 and inhibits p53. Nature Cell Biol., 8:855-862, 2006.
Grimberg, A., Coleman, C.M., Shi, Z., Burns, T.F., MacLachlan, T., Wang, W., and El-Deiry, W.S. Insulin-Like Growth Factor Binding Protein-2 is a Novel Mediator of p53 Inhibition of Insulin-Like Growth Factor Signaling. Cancer Biol. Ther., 5:1408-1413, 2006.
Wang, W., and El-Deiry, W.S. Small molecule modulators of p53 family signaling and anti-tumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. USA, 103:11003-11008, 2006.
Yang, W-S., Rozan, L.M., McDonald, E.R., III, Matthew, E., Wang, W., Dicker, D.T., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARPs) 1/2 are novel ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem., 282:3273-3281, 2007.
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. Accompanying News Feature
Laguinge, L.M., Samara, R.N., Wang, W., El-Deiry, W.S., Corner, G., Augenlicht, L., Mishra, L., and Jessup, J.M. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Research, 68:909-917, 2008.
Kuribayashi, K., Krigsfeld, G., Wang, W., Xu, J., Mayes, P.A., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7:2034-2038, 2008.
Lu, C., Wang, W, and El-Deiry, W.S. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol. Ther. 7:2039-2046, 2008.
Huang, C., Zhang, X.M., Tavaluc, R.T., Hart, L.S., Dicker, D.T., Wang, W., and El-Deiry, W.S. The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol. Ther. 8:2184-2191, 2009.
Allen, J.E., Hart, L.S., Dicker, D.T., Wang, W., and El-Deiry, W.S. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol. Ther. 8:2192-2203, 2009.
Katz, S.I., Zhou, L., Chao, G., Smith, C.D., Ferrara, T., Wang, W., Dicker, D.T., and El-Deiry, W.S. Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol. Ther., 8:2406-2416, 2009.
McGovern, P.E., Christofidou-Solomidou, M., Wang, W., Dukes, F., Davidson, T., and El-Deiry, W.S. Anticancer activity of botanical compounds in ancient fermented beverages. Int. J. Oncol., 37:5-14, 2010.
Dews, M., Fox, J.L., Hultine, S., Sundaram, P., Wang, W., Liu, Y.Y., Furth, E., Enders, G.H., El-Deiry, W., Schelter, J.M., Cleary, M.A., and Thomas-Tikhonenko, A. The myc-miR-17-92 axis blunts TGB-beta signaling and production of multiple TGF-beta-dependent antiangiogenic factors. Cancer Res., 70:8233-8246, 2010.
Katz, S.I., Zhou, L., Ferrara, T., Wang, W., Mayes, P.A., Smith, C., and El-Deiry, W.S. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int. J. Oncol., 39:91-100, 2011.
Wang, W., Gallant, J-N., Katz, S.I., Dolloff, N.G., Smith, C.D., Abdulghani, J., Allen, J.E., Dicker, D.T., Hong, B., Navaraj, A., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther., 12:229-238, 2011.
Gallant, J-N., Allen, J.E., Smith, C.D., Dicker, D.T., Wang, W., Dolloff, N.G., Navaraj, A., and El-Deiry, W.S. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther., 12:239-251, 2011.
Zhou, L., Wang, W., Dicker, D.T., Humphreys, R.C., and El-Deiry, W.S. Prediction of proapoptotic anti-cancer therapeutic response in-vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biol. Ther., 12:335-348, 2011.
Zhou, L., El-Deiry, W., Wang, W., Ingram, M.E., and Katz, S.I. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncol. Rep. 28:883-888, 2012.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Wang, W., and El-Deiry, W.S. CP-31398 stabilizes wild-type p53 by inhibiting p53 ubiquitination without inducing serine 20 phosphorylation or reduced interaction with MDM2. AACR 93rd Annual meeting, San Francisco, CA 2002.
Wang, W., Rastinejad, F., and El-Deiry, W.S. CP31398-mediated enhancement and bioluminescent imaging of p53 activity following p53 therapeutic gene transfer to human cancer cells subsequently treated with TRAIL. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Fei, P., Wang, W., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Wang, W., Li, Y., and El-Deiry, W.S. Bioluminescent imaging of p53 activity and screening for potent chemicals that rescue or enhance transcriptional activity of p53 and its family members in tumor cells. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Wang, W., and El-Deiry, W.S. CP-31398 Induction of Death Receptor 5 by Blockade of Protein Degradation Sensitizes Tumor Cells to TRAIL. AACR 96th Annual Meeting, Anaheim, California, 2005.
Ricci, M.S., Kim, S-H., Plastaras, J., Flaherty, K., Wang, W., Smith, C. and El-Deiry, W.S. Repression of TRAIL induced c-IAP2 and Mcl-1 by c-Myc or Bay 43-9006 sensitizes Bax-deficient cells to TRAIL-induced death. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov., 2005.
Wang, W., and El-Deiry, W.S. Screening and anti-tumor effects of small molecules that trigger p53 transcriptional activity in p53-deficient tumor cells. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov., 2005.
Wang, W., Kim, S-H., Dicker, D.T., and El-Deiry, W.S. RbBP5 differentially regulates TRAIL and adriamycin-induced apoptosis in tumor cells. 97th Annual AACR meeting, Washington, D.C., April 2006.
Yang, W-S., Rozan, L., Wang, W., Matthew, E., Dicker, D.T., and El-Deiry, W.S. CARPs negatively regulate levels of phosphorylated p53. 97th Annual AACR meeting, Washington, D.C., April 2006.
Wang, W., and El-Deiry, W.S. DNA-intercalating drugs activate p53 transcriptional responses without evidence of DNA-damage signaling. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Zhou, L., Dicker, D.T., Wang, W., and El-Deiry, W.S. Prediction of proapoptotic anticancer therapeutic response by optical imaging of death inducing ligand-receptor interaction. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Zhou, L., Dicker, D.T., Wang, W., and El-Deiry, W.S. Prediction of pro-apoptotic anti-cancer therapeutic response by visualization of death receptors and specific markers of apoptosis. 100th Annual AACR meeting, Denver, CO, April 2009.
Wang, W., and El-Deiry, W.S. p53 and p73 transactivate the proapoptotic early growth response factor, EGR2, and its expression is induced by small molecules that restore p53 signaling in tumor cells. 100th Annual AACR meeting, Denver, CO, April 2009.
Dews, M., Hultine, S., Wang, W., Liu, Y., Enders, G., Furth, E., El-Deiry, W., and Thomas-Tikhonenko, A. Clusterin, an inhibitor of tumor growth and angiogenesis, is negatively regulated by c-Myc through miR-17-92 and the type II TGF receptor. Keystone meeting “MicroRNA and Cancer,” June 2009.
Wang, W., Katz, S.I., Abdulghani, J., Dicker, D., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL via up-regulating DR5 and eradicating MCL-1. 101st Annual AACR meeting, Washington, D.C., April 2010.
Gallant, J-N., Wang, W., Dolloff, N.G., Allen, J.E., and El-Deiry, W.S. Novel combinatorial Quinacrine cancer therapies for advanced colon cancer. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
van den Heuvel, A.P.J., Wang, W., Kopelovich, L., and El-Deiry, W.S. A screen to identify novel p53 family member activity-restoring compounds with a focus on p73. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Wang, W., Rastinejad, F., and El-Deiry, W.S. Restoring p53-Dependent Tumor Suppression. Cancer Biology and Therapy, 2:S55-S63, 2003.
Wang, W., and El-Deiry, W.S. Targeting FOXO kills two birds with one stone. Chem Biol., 11:16-18, 2004.
Wang, W., and El-Deiry, W.S. Targeting p53 by PTD-mediated transduction. Trends Biotechnol., 22:431-434, 2004.
Wang, W., and El-Deiry, W.S. Restoration of p53 to limit tumor growth. Curr. Opin. in Oncol., 20:90-96, 2008.
Bassett, E.A., Wang, W., Rastinejad, F., and El-Deiry, W.S. Structural and functional basis for therapeutic modulation of p53 signaling. Clin. Cancer Res., 14:6376-6386, 2008.
Chen, F., Wang, W., and El-Deiry, W.S. Current strategies to target p53 in cancer. Biochemical Pharmacology, 80:724-730, 2010.

Niklas Finnberg, PhD
2003 - 10, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania
Assistant Professor, Hematology-Oncology, Penn State Hershey Cancer Institute

Original Publications
Lin, S.W., Cook, M., Finnberg, N., Bernhard, E., Baldwin, D., and El-Deiry, W.S. p53-Dependent Induction of Serine Proteases in Irradiated Mouse Colon. Cancer Biol. Ther. 3:1290-1297, 2004.
Finnberg, N., Gruber, J.J., Fei, P., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., McKenna, W.G., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. DR5 knock-out mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol., 25:2000-13, 2005.
Finnberg, N., Kim, S-H., Furth, E.E., Liu, J.J., Russo, P., Piccoli, D.A., Grimberg, A., and El-Deiry, W.S. Noninvasive Fluorescence Imaging of Cell Death in Fresh Human Colon Epithelia Treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol. Ther., 4:937-942, 2005.
Finnberg, N., Klein-Szanto, A.J.P., and El-Deiry, W.S. TRAIL-R knockout promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest., 118:111-123, 2008.
Finnberg, N., Wambi, C., Ware, J.H., Kennedy, A.R., and El-Deiry, W.S. Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation in mice in vivo. Cancer Biol. Ther. 7:2023-2033, 2008.
Wambi, C.O., Sanzari, J.K., Sayers, C.M., Nuth, M., Zhou, Z., Davis, J., Finnberg, N., Lewis-Wambi, J.S., Ware, J.H., El-Deiry, W.S., and Kennedy, A.R. Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat. Res. 172:175-186, 2009.
Navaraj, A., Finnberg, N., Dicker, D.T., Yang, W., Matthew, E.M., and El-Deiry, W.S. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol. Ther., 8:2417-2444, 2009.
Kuribayashi, K., Finnberg, N., Jeffers, J.R., Zambetti, G.P., and El-Deiry, W.S. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle, 10:2380-2389, 2011.
Finnberg, N.K., Hart, L.S., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. American J. Pathol., 179:2169-2176, 2011.
Kline, C.L., Sheikh, H.S., Scicchitano, A., Gingrich, R., Beachler, C., Finnberg, N.K., Liao, J., Sivik, J., and El-Deiry, W.S. Preliminary observations indicate variable patterns of plasma 5-Fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol. Ther., 12:557-568, 2011.
Cazanave, S.C., Mott, J.L., Bronk, S.F., Werneburg, N.W., Fingas, C.D., Meng, X.W., Finnberg, N., El-Deiry, W.S., Kaufmann, S.H., Gores, G.J. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J. Biol. Chem., 286:39336-39348, 2011.
Zhi-long Ma, J., Yang, J., Qin, J.S., Richter, A., Perret, R., El-Deiry, W.S., Finnberg, N., and Ronchese, F. Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. Oncoimmunology 1:1507-1516, 2012.
Abstracts
Gruber, J.J., Fei, P., Finnberg, N., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. KILLER/DR5 knock-out mice are compromised in radiation-induced apoptosis. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Finnberg, N.K., Matthew, E., Bernhard, E., Klein-Szanto, A., and El-Deiry, W.S. Decreased survival, chronic inflammation and tumor susceptibility of irradiated DR5-null mice. 97th Annual AACR meeting, Washington, D.C., April 2006.
Finnberg, N.K., and El-Deiry, W.S. Expression profiling of TRAIL receptor deficient murine E-myc B cell lymphomas identifies potential candidate target genes for modulation of TRAIL-sensitivity. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Finnberg, N., Wambi, C., Ware, J.H., Kennedy, A.R., and El-Deiry, W.S. An in vivo investigation in mice of the acute apoptotic response following proton-beam radiation. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Finnberg, N.K., and El-Deiry, W.S. GI-toxicity in mice in vivo following targeting of TRAIL-R in combination with CPT-11 and 5-fluorouracil. 100th Annual AACR meeting, Denver, CO, April 2009.
Finnberg, N.K., Lang, K., Arunasalam, N., Motoyama, N., Zhou, B-B., and El-Deiry, W.S. Chk2 triggers expression of XIAP in the murine colonic epithelium following treatment with 5-FU but not CPT-11. 100th Annual AACR meeting, Denver, CO, April 2009.
Finnberg, N.K., Arunasalam, N., Lang, K., Cerniglia, G., Motoyama, N., Zhou, B-B., and El-Deiry, W. Targeting of DR5/TRAIL-R2 in combination with irinotecan triggers p53- and chk2-dependent gastrointestinal toxicity in mice in vivo and synergistic cell death in human gastrointestinal epithelial cells in vitro. 101st Annual AACR meeting, Washington, D.C., April 2010.
Hart, L.S., Finnberg, N., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., Thomas-Tikhonenko, A., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Finnberg, N.K., Arunasalam, N., Lang, K., Cerniglia, G., Motoyama, N., Zhou, B-B., and El-Deiry, W.S. Chk2-inhibition promotes increased killing of human colorectal cancer cells and protects from gastrointestinal toxicity following irinotecan/TRAIL death receptor agonists (TDRA). 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Abdulghani, J., Gallant, J., Whitcomb, T., Dicker, D., Goldenberg, D., Smith, C.D., Finnberg, N., and El-Deiry, W.S. Quinacrine and sorafenib combination as potential therapy for anaplastic thyroid cancer. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Finnberg, N., and El-Deiry, W.S. Activating FOXO3a, NF-kappaB and p53 by Targeting IKKs: An Effective Multi-Faceted Targeting of the Tumor-Cell Phenotype? Cancer Biol. Ther., 3:614-616, 2004.
Finnberg, N., and El-Deiry, W.S. Paclitaxel and velcade: the rationale for a combo. Cancer Biol. Ther. 4:631-634, 2005.
Finnberg, N., and El-Deiry, W.S. Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neo-adjuvant or adjuvant therapies. Clin. Cancer Res., 12:4132-4136, 2006.
Finnberg, N., and El-Deiry, W.S. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle, 7:1525-1528, 2008.

Nathan Dolloff, PhD
2007 - 11, post-doctoral fellow, El-Deiry Lab, University of Pennsylvania and Penn State University
Assistant Professor, Hematology-Oncology, Penn State University

Original Publications
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., Dicker, D.T., Henske, E.P., and El-Deiry, W.S. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle, 8:4168-4175, 2009.
Hart, L.S., Dolloff, N.G., Dicker, D.T., Koumenis, C., Christensen, J.G., Grimberg, A., and El-Deiry, W.S. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle, 10:2331-2338, 2011.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Dolloff, N.G., Mayes, P.A., Hart, L.S., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Off-target Lapatinib activity derives from TRAIL death receptor up-regulation. Science Translational Medicine, 3:92-102, 2011.
Wang, W., Gallant, J-N., Katz, S.I., Dolloff, N.G., Smith, C.D., Abdulghani, J., Allen, J.E., Dicker, D.T., Hong, B., Navaraj, A., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther., 12:229-238, 2011.
Gallant, J-N., Allen, J.E., Smith, C.D., Dicker, D.T., Wang, W., Dolloff, N.G., Navaraj, A., and El-Deiry, W.S. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther., 12:239-251, 2011.
Dolloff, N.G., Ma, X., Dicker, D.T., Humphreys, R.C., Li, L.Z., and El-Deiry, W.S. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol. Ther., 12:349-356, 2011.
Finnberg, N.K., Hart, L.S., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. American J. Pathol., 179:2169-2176, 2011.
Dolloff, N.G., Allen, J.E., Dicker, D.T., Aqui, N., Vogl, D., Malysz, J., Talamo, G., and El-Deiry, W.S. Sangivamycin-Like Molecule 6 (SLM6) exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9 (CDK9). Molecular Cancer Therapeutics, 11:2321-2330, 2012.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Dolloff, N.G., Mayes, P.A., Dicker, D.T., Humphreys, R.C., and El-Deiry, W.S. Novel target of lapatinib enhances anti-tumor activity via TRAIL sensitization. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Dolloff, N., Mayes, P., Dicker, D.T., and El-Deiry, W.S. Lapatinib enhances TRAIL sensitivity in colorectal cancer cells via a novel EGFR/HER2-independent mechanism involving JNK activation and DR5 up-regulation. 100th Annual AACR meeting, Denver, CO, April 2009.
Matthew, E.M., Hart, L.S., Astrinidis, A., Navaraj, A., Dolloff, N.G., and El-Deiry, W.S. The role of DNA damage-inducible Polo-like kinase 2 as a tumor suppressor and target for therapy. 100th Annual AACR meeting, Denver, CO, April 2009.
Dolloff, N.G., Hart, L.S., Mayes, P.A., and El-Deiry, W.S. Dual GSK-3/CDK inhibitors induce multiple myeloma cell death and eliminate putative cancer stem cell populations. 101st Annual AACR meeting, Washington, D.C., April 2010.
Dolloff, N.G., Hart, L.S., Mayes, P.A., Dicker, D.T., Humphreys, R.C., Gilmer, T.M., and El-Deiry, W.S. Novel anti-tumor activity of lapatinib derives from off-target up-regulation of TRAIL death receptors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Hart, L.S., Finnberg, N., Dolloff, N.G., Rodgers, Z.B., Dicker, D.T., Thomas-Tikhonenko, A., and El-Deiry, W.S. High-resolution imaging and anti-tumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Dolloff, N.G., Mayes, P., Dicker, D., and El-Deiry, W. Sangivamycin-like molecules (SLMs) suppress the expression of oncogenic gene translocation products and induce apoptosis of multiple myeloma cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Navaraj, A., Dicker, D.T., Dolloff, N., and El-Deiry, W.S. Multiplexed detection of phospho-ERK as a marker of H-Ras signaling, EGFR and cancer stem cell marker expression in breast cancer cells recovered from human blood. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Gallant, J-N., Wang, W., Dolloff, N.G., Allen, J.E., and El-Deiry, W.S. Novel combinatorial Quinacrine cancer therapies for advanced colon cancer. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Dolloff, N.G., Mayes, P., Hart, L., Dicker, D., and El-Deiry, W.S. Off-target lapatinib activity upregulates TRAIL death receptors in colon cancer cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Dolloff, N.G., Talamo, G., Dicker, D.T., and El-Deiry, W.S. Sangivamycin-Like Molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, San Francisco, CA, November, 2011.
Dolloff, N.G., Zhou, L., Peters, K., Navaraj, A., Allen, J.E., Das, A., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Lim, B., Dolloff, N.G., Allen, J.E., Dicker, D.T. and El-Deiry, W.S. Lapatinib restores TRAIL-mediated apoptosis in TRAIL-resistant Triple Negative Breast Cancer (TNBC) through an off-target strategy that appears to be independent of increased death receptor expression. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Warfel, N.A., Dolloff, N.G., and El-Deiry, W.S. Cyclin Dependent Kinase 1 regulates HIF-1 expression to promote tumorigenesis. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Yang, W. Dolloff, N.G., and El-Deiry, W.S. ERK and MDM2 prey on FOXO3a. Nature Cell Biol., 10:125-126, 2008.
Faltas, B., Zeidan, A., Peters, K., Das, A., Joudeh, J., Navaraj, A., Dolloff, N.G., Harvey, H.A., Jiang, Y., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J. Clin. Oncol., 29:2947-2948, 2011.

Kristi Peters, PhD
2010 - 11, post-doctoral scientist, El-Deiry Lab, Penn State University
Staff Scientist

Original Publications
Patel, A.S., Allen, J.E., Dicker, D.T., Peters, K.L., Sheehan, J.M., Glantz, M.J., and El-Deiry, W.S. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget, 2:752-760, 2011.
Abstracts
Peters, K.L., Allen, J.E., Dicker, D.T., Das, A., Joudeh, J., and El-Deiry, W.S. CTC profiling: Integration of biomarker analysis with current Veridex CellSearch technology. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Das, A., Allen, J.E., Dicker, D.T., Peters, K.L., Joudeh, J., and El-Deiry, W.S. Quantum Dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Das, A., Joudeh, J., Peters, K.L., Allen, J.E., Zheng, S., Dicker, D.T., Yang, Z., and El-Deiry, W.S. A population of metastatic colorectal cancer (mCRC) patients with radiologically proven liver metastasis and EpCAM expressing primary tumors show low circulating tumor cell counts by Veridex CellSearch. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Das, A., Whitcomb, T.L., Allen, J.E., Dicker, D.T., Peters, K.L., El-Deiry, W.S. Isolation and characterization of circulating tumor cells in an orthotopic mouse model of colorectal cancer. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Peters, K.L., Dicker, D.T., Abdallah, K., Dhar, A., Woolfson, A., and El-Deiry, W.S. The IGF1 inhibitor BMS-754807 synergizes with Lapatinib in colorectal cancer cell lines. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Dolloff, N.G., Zhou, L., Peters, K., Navaraj, A., Allen, J.E., Das, A., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Kaifi, J.T., Kunkel, M., Allen, J.E., Dicker, D.T., Peters, K.L., Das, A., Kimchi, E.T., Staveley-O’Carroll, K.F., and El-Deiry, W.S. Circulating tumor cell numbers in colorectal cancer patients with different metastatic spread patterns. American College of Surgeons’ 98th Annual Clinical Congress, Chicago, IL, Sept 30-Oct 4, 2012.
Peters, K.L., Dicker, D.T., Finckenstein, F.G., Woolfson, A., and El-Deiry, W.S. The IGF1 receptor/insulin receptor dual kinase inhibitor BMS-754807 targets the cancer stem cell population in addition to its synergism with Lapatinib in colorectal cancer. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Faltas, B., Zeidan, A., Peters, K., Das, A., Joudeh, J., Navaraj, A., Dolloff, N.G., Harvey, H.A., Jiang, Y., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J. Clin. Oncol., 29:2947-2948, 2011.

Arunasalam Navaraj, DVM, PhD
2010 - 13, post-doctoral scientist, El-Deiry Lab, Penn State University

Roslyn Crowder, PhD

2008 - 13 post-doctoral scientist, El-Deiry Lab, U. Penn and Penn State

Bo Hong, PhD

2010 - 13 post-doctoral scientist, El-Deiry Lab, Penn State Univ.

Avisnata Das, MD

2010 - 13 post-doctoral scientist, El-Deiry Lab, Penn State Univ.

Noel Warfel, PhD

2011 - 13 post-doctoral scientist, El-Deiry Lab, Penn State Univ.

Pieter van den Heuvel, PhD

2012 - 13 post-doctoral scientist, El-Deiry Lab, Penn State Univ.

Lab Alumni - Predoctoral

Kyran O. Mitchell (MD, PhD Student)
1996 - 2000, PhD thesis student, El-Deiry Lab, University of Pennsylvania
University of Pennsylvania School of Medicine
Resident in Surgery, Brigham and Women's Hospital (03-08)

Original Publications
Yeh, W.-C., de la Pompa, J.L., McCurrach, M.E., Shu, H.-B., Elia, A.J., Shahinian, A., Ng, M., Wakeham, A., Mitchell, K., El-Deiry, W.S., Lowe, S.W., Goeddel, D.V., and Mak, T.W. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science, 279:1954-1958, 1998.
Mitchell, K., and El-Deiry, W.S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth and Diff., 10:223-230, 1999.
Park, J.-S., Boyer, S., Mitchell, K., Gilfor, D., Birrer, M., Darlington, G., El-Deiry, W., Firestone, G.L., Munger, K., Band, V., Fisher, P.B., and Dent, P. Expression of human papillomavirus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21Cip-1/WAF1/MDA6. J. Biol. Chem. 275:18-28, 2000.
Mitchell, K.O., Ricci, M.S., Miyashita, T., Reed, J.C., and El-Deiry, W.S. Identification of Bax as a transcriptional target and mediator of c-Myc-induced apoptosis. Cancer Research, 60:6318-6325, 2000.
Abstracts
Mitchell, K.O., and El-Deiry, W.S. c-Myc must inhibit p21WAF1/CIP1 to deregulate S-phase. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Mitchell, K.O., and El-Deiry, W.S. c-Myc-dependent repression of p21(WAF1/CIP1) expression correlates with S-phase entry in TPA-sensitive human cancer cells. 90th Annual AACR Meeting, Philadelphia, Pennsylvania. Abstract No. 4796, April 1999.
Mitchell, K.O., Miyashita, T., Reed, J.C., and El-Deiry, W.S. Identification of bax as a c-myc target gene. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Mitchell, K.O., Ricci, M.S., Miyashita, T., Dicker, D.T., Jin, Z.-Y., Reed, J.C., and El-Deiry, W.S. Bax as a transcriptional target and mediator of c-Myc-induced apoptosis. Gordon Research Conference on Cancer, Salve Regina University, Newport, RI, August 2000.

Raymond D. Meng (MD, PhD Student)
1997 - 2000, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Resident, Department of Medicine, Duke University (01-04)
MSKCC Hem/Onc Fellowship 2004 (Chief fellow '05-'06)
2007 - Assistant Attending Physician, MSKCC
2011 - Assistant Medical Director, Early Clinical Development, Genentech

Original Publications
Zeng, Y.-X., Prabhu, N.S., Meng, R., and El-Deiry, W.S. Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int. J. Oncol., 11:221-226, 1997.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics, 17:141-143, 1997.
Meng, R., Shih, H., Prabhu, N., George, D., and El-Deiry, W.S. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res., 4:251-259, 1998.
Meng, R.D., Phillips, P., and El-Deiry, W.S. p53-independent increase in E2F1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int. J. Oncol., 14:5-14, 1999.
Wu, G.S., Burns, T.F., McDonald, E.R., III, Meng, R.D., Kao, G., Muschel, R., Yen, T., and El-Deiry, W.S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not G1 arrest. Oncogene, 18:6411-6418, 1999.
Meng, R.D., McDonald, E.R., III, Sheikh, M.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Molecular Therapy, 1:130-144, 2000.
Meng, R.D., and El-Deiry, W.S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-. Exp. Cell Research, 262:154-169, 2001.
McGarvey, T.W., Meng, R.D., Johnson, O., El-Deiry, W., and Malkowicz, S.B. Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. Urol. Oncol. 6:155-162, 2001.
Abstracts
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated cell death receptor on chromosome 8p21. Second World Congress in Oncology. Athens, Greece, October 16-18, 1997.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated death receptor on chromosome 8p21. NATO Advanced Research Workshop at H. Lee Moffitt Cancer Center and Research Institute, Univ. of South Florida, December 5-9, 1997.
Meng, R.D., Phillips, P., and El-Deiry, W.S. Ad-p21 bypass of a post-Rb block to p53-dependent growth inhibition in human glioma cells may involve E2F1. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Wu, G.S., Burns, T.F., McDonald, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5 as a DNA damage-inducible p53-regulated cell receptor gene. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Wu, G.S., Burns, T.F., Meng, R.D., and El-Deiry, W.S. Involvement of TRAIL death receptor signaling in p53-dependent apoptosis. 9th International p53 Workshop, Crete, May 9-13, 1998.
Meng, R.D., Burns, T.F., McDonald, E.R., III, Sheikh, M.S., Wu, G.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD is induced by p53 overexpression but does not prevent KILLER/DR5- or p53-dependent colon cancer suppression. 90th Annual AACR Meeting, Philadelphia, Pennsylvania. Abstract No. 1124, April 1999.
Meng, R.D., and El-Deiry, W.S. Regulation of KILLER/DR5 TRAIL receptor expression by p53-dependent and-independent pathways. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 1125, April 1999.
Wu, G.S., Burns, T.F., Meng, R.D., and El-Deiry, W.S. p53-dependent induction of KILLER/DR5 in cells undergoing apoptosis but not cell cycle arrest. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 670, April 1999.
Meng, R.D., McDonald, E.R., III, Sheikh, M.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD is induced by p53 overexpression and delays p53- and KILLER/DR5-dependent colon cancer apoptosis. Workshop “p53: Twenty Years On,” May 1999, Trieste, Italy.
Chapters and Reviews
Meng, R.D. and El-Deiry, W.S. Tumor Suppressor Gene Therapy for Cancer: From the Bench to the Clinic. In Drug Resistance Updates. Georgopapadakou, N.H. and Broxterman, H., eds. Churchill Livingstone (UK). 1:205-210, 1998.
Meng, R., and El-Deiry, W.S. Tumor Suppressor Genes as Targets for Cancer Gene Therapy. In Gene Therapy of Cancer. Gerson, S.L. & Lattime, E.C., eds. Academic Press. (1999) San Diego, 3-20.
MacLachlan, T., Meng, R.D., and El-Deiry, W.S. “p53: 20 years on.” Report on meeting in Trieste, Italy, May 1999, J. Cell Phys. 181:371-374, 1999.
Meng, R.D., and El-Deiry, W.S. Clinical applications of tumor supressor gene therapy. In Gene Therapy of Cancer, Second Edition. Lattime, E.C., and Gerson, S.L., Eds. Academic Press, San Diego, CA, pp. 273-278, 2002.
Meng, R.D., and El-Deiry, W.S. Cancer gene therapy with tumor suppressor genes involved in cell-cycle control. In Gene Therapy of Cancer, Second Edition. Lattime, E.C., and Gerson, S.L., Eds. Academic Press, San Diego, CA, pp. 279-297, 2002.
Meng, R.D., and El-Deiry, W.S. Cancer gene therapy with the p53 tumor suppressor gene. In Gene Therapy of Cancer, Second Edition. Lattime, E.C., and Gerson, S.L., Eds. Academic Press, San Diego, CA, pp. 299-313, 2002.

Nesrin Ozoren (PhD, Biology)
1998 - 2002, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Post-doc with Gabriel Nunez, University of Michigan

2005 - Assistant Professor, Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey
2008 - Associate Professor, Bogazici University

Original Publications
Pai , S.I., Wu, G.S., Ozoren, N., Wu, L., Jen, J., Sidransky, D., and El-Deiry, W.S. Germline loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res., 58:3513-3518, 1998.
Ozoren, N., Fisher, M.J., Kim, K., Liu, C.X., Genin, A., Shifman, Y., Dicker, D.T., Spinner, N.B., Lisitsyn, N.A., and El-Deiry, W.S. Homozygous deletion of DR4 in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol., 16:917-925, 2000.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to TRAIL. Cancer Res., 60:6259-6265, 2000.
Ozoren, N., and El-Deiry, W.S. Heat Shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp. Cell Research, 281:175-181, 2002.
Ozoren, N., and El-Deiry, W.S. Defining characteristics of Type I and Type II apoptotic cells in response to TRAIL. Neoplasia, 4:551-557, 2002.
Abstracts
Ozoren, N., Fisher, M., Kim, K.-H., Liu, C.-X., Lisitsyn, N.A., and El-Deiry, W.S. A homozygous deletion of the DR4 TRAIL death receptor gene is associated with TRAIL resistance of FaDu nasopharyngeal carcinoma cells. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 4601, April 1999.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. Caspase 9 inhibition allows TRAIL-induced killing of cancer cells while protecting normal human liver cells. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 1713, March 2001.
Chapters and Reviews
Ozoren, N. and El-Deiry, W.S. Introduction to cancer genes and growth control. In DNA Alterations in Cancer: Genetic and Epigenetic Changes. Ehrlich, M., Ed. Eaton Publishing, Natique, MA, pp. 3-43, 2000.
Ozoren, N., and El-Deiry, W.S. Cell Surface Death Receptor Signaling in Normal and Cancer Cells. Seminars in Cancer Biology, 13:135-147, 2003.

Joanna K. Sax (Cell and Molecular Biology)
2000 - 03, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Attending Law School at U. Penn
2006 - Legal Associate, Morgan Lewis & Bockius, LLP, San Francisco
2009 - Faculty, California Western Law School

Original Publications
Sax, J.K., Dash, B.C., Hong, R., Dicker, D.T., and El-Deiry, W.S. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21(WAF1/CIP1) expression. Cell Cycle, 1:90-96, 2002.
Sax, J.K., Fei, P., Murphy, M.E., Bernhard, E.J., Korsmeyer, S.J., and El-Deiry, W.S. BID transcriptional regulation by p53 contributes to chemosensitivity. Nature Cell Biology, 4:842-849, 2002.
Sax, J.K., and El-Deiry, W.S. Identification and characterization of the cytoplasmic protein TRAF4 as a p53 regulated pro-apoptotic gene. J. Biol. Chem., 278:36435-36444, 2003.
Sax, J.K., Stoddard, A., Murphy, M.E., Chodosh, L., and El-Deiry, W.S. Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol. Ther., 2:416-430, 2003.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Abstracts
Sax, J.K., Hong, R., Dash, B.C., and El-Deiry, W.S. The CDK inhibitor butyrolactone is a potent inhibitor of p21(WAF1/CIP1) expression. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 717, March 2001.
Sax, J.K., Burns, T.F., Murphy, M.E., and El-Deiry, W.S. Identification and characterization of TRAF4 as a p53-regulated gene. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Chapters and Reviews
Sax, J.K., and El-Deiry, W.S. Commentary on “Specific protection against breast cancers by cyclin D1 ablation,” Womens Oncol. Rev. 1:241-242, 2001.
Sax, J., and El-Deiry, W.S. CDK inhibitors as targets of chemoprevention agents. In Cell Cycle Inhibitors in Cancer Therapy: Current Strategies. Giordano, A., and Soprano, K.J., Eds. Humana Press, Totowa, NJ, pp.119-143, 2003.
Sax, J.K., and El-Deiry, W.S. p53 Downstream Targets and Chemosensitivity. Cell Death Diff., 10:413-417, 2003.

E. Robert McDonald, III (Cell and Molecular Biology)
1996 - 2003, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Post-doc with Steve Elledge at Harvard
2009 - Scientist, Novartis Institutes for BioMedical Research; Oncology, Drug Discovery I

Original Publications
McDonald, E.R., III, Wu, G.S., Waldman, T., and El-Deiry, W.S. Repair Defect in p21WAF1/CIP1-/- Cells. Cancer Res., 56:2250-2255, 1996.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics, 17:141-143, 1997.
Wu, G.S., Burns, T.F., McDonald, E.R., III, Meng, R.D., Kao, G., Muschel, R., Yen, T., and El-Deiry, W.S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not G1 arrest. Oncogene, 18:6411-6418, 1999.
Meng, R.D., McDonald, E.R., III, Sheikh, M.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Molecular Therapy, 1:130-144, 2000.
McDonald, E.R., III, Chui, P.C., Martelli, P.F., Dicker, D.T., and El-Deiry, W.S. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J. Biol. Chem., 276:14939-14945, 2001.
Corn, P.G., McDonald, E.R., III, Herman, J.G. and El-Deiry, W.S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von-Hippel-Lindau protein. Nature Genetics, 35:229-237, 2003.
Jin, Z., McDonald, E.R., III, Dicker, D.T., and El-Deiry, W.S. Deficient TRAIL Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-Induced Apoptosis. J. Biol. Chem., 279:35829-35839, 2004.
McDonald, E.R., III, and El-Deiry, W.S. Suppression of caspase-8- and –10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc. Natl. Acad. Sci. USA, 101:6170-6175, 2004.
Tibbetts, M.D., Shiozaki, E.N., Gu, L., McDonald, E.R. 3rd, El-Deiry, W.S., and Shi, Y. Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. Structure 12:2257-63, 2004.
Yang, W-S., Rozan, L.M., McDonald, E.R., III, Matthew, E., Wang, W., Dicker, D.T., and El-Deiry, W.S. Caspase-8/-10 associated RING domain proteins (CARPs) 1/2 are novel ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem., 282:3273-3281, 2007.
Abstracts
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated cell death receptor on chromosome 8p21. Second World Congress in Oncology. Athens, Greece, October 16-18, 1997.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated death receptor on chromosome 8p21. NATO Advanced Research Workshop at H. Lee Moffitt Cancer Center and Research Institute, Univ. of South Florida, December 5-9, 1997.
Wu, G.S., Burns, T.F., McDonald, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5 as a DNA damage-inducible p53-regulated cell receptor gene. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Meng, R.D., Burns, T.F., McDonald, E.R., III, Sheikh, M.S., Wu, G.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD is induced by p53 overexpression but does not prevent KILLER/DR5- or p53-dependent colon cancer suppression. 90th Annual AACR Meeting, Philadelphia, Pennsylvania. Abstract No. 1124, April 1999.
McDonald, E.R., III, Martelli, P.F., Srinivasula, S.M., Alnemri, E.S., and El-Deiry, W.S. Determinants of apoptosis induction by the TRAIL receptor KILLER/DR5. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 1118, April 1999.
Meng, R.D., McDonald, E.R., III, Sheikh, M.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD is induced by p53 overexpression and delays p53- and KILLER/DR5-dependent colon cancer apoptosis. Workshop “p53: Twenty Years On,” May 1999, Trieste, Italy.
McDonald, E.R., III, Chui, P., and El-Deiry, W.S. Extensive alanine scanning mutagenesis of the death domain of the TRAIL receptor KILLER/DR5 reveals critical determinants of apoptotic signaling. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
McDonald, E.R., Dicker, D.T., and El-Deiry, W.S. CARP, a novel caspase 8 and 10-associated regulatory protein which alters apoptotic potential. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 2968, March 2001.
Corn, P.G., McDonald, E.R., Herman, J.G., and El-Deiry, W.S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von hippel-lindau protein. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Chapters and Reviews
McDonald, R.E., III, and El-Deiry, W.S. Cell cycle control as a basis for cancer drug development. Int. J. Oncol. 16:871-886, 2000.
McDonald, E.R., III, and El-Deiry, W.S. Checkpoint genes in cancer. Annals of Medicine 33:113-122, 2001.
McDonald, E.R., III, and El-Deiry, W.S. Yeast two hybrid screening as a means of deciphering tumor suppressor pathways. In Tumor Suppressor Genes. Methods in Molecular Biology Series. El-Deiry, W.S., Ed. Humana Press, Totowa, NJ, 223:173-185, 2003.
McDonald, E.R. III, and El-Deiry, W.S. Mammalian cell death pathways: Intrinsic and extrinsic. In Death Receptors in Cancer Therapy. Cancer Drug Discovery and Development Series. El-Deiry, W.S., Ed. Humana Press, Totowa, NJ, pp. 1-41, 2004.

Timothy F. Burns (M.D., Ph.D. Student)
1997-2003, PhD thesis student, El-Deiry Lab, University of Pennsylvania
2005 - Medical Residency at Johns Hopkins
2008 - Oncology Fellowship at Johns Hopkins
2012 - Assistant Professor, Univ. of Pittsburgh Medical Center and Cancer Institute

Original Publications
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics, 17:141-143, 1997.
Sheikh, M.S., Burns, T.F., Huang, Y., Wu, G.S., Amundson, S., Brooks, K.S., Fornace, A.J., Jr., and El-Deiry, W.S. p53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and TNF. Cancer Res., 58:1593-1598, 1998.
Wu, G.S., Burns, T.F., McDonald, E.R., III, Meng, R.D., Kao, G., Muschel, R., Yen, T., and El-Deiry, W.S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not G1 arrest. Oncogene, 18:6411-6418, 1999.
Somasundaram, K., MacLachlan, T.K., Burns, T.F., Sgagias, M., Cowan, K., Weber,B.L., and El-Deiry, W.S. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene, 18:6605-6614, 1999.
Wu, G.S., Burns, T.F., Zhan, Y., Alnemri, E.S., and El-Deiry, W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 TRAIL death receptor. Cancer Res., 59:2770-2775, 1999.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to TRAIL. Cancer Res., 60:6259-6265, 2000.
Burns, T.F., Bernhard, E.J., and El-Deiry, W.S. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene, 20:4601-4612, 2001.
Burns, T.F. and El-Deiry, W.S. Identification of Inhibitors of TRAIL-Induced Death (ITIDs) in the TRAIL sensitive colon carcinoma cell line, SW480, using a genetic approach. J. Biol. Chem, 276:37879-37886, 2001.
Suliman, Y., Opitz, O.G., Avadhani, A., Burns, T.F., El-Deiry, W.S., Wong, D., and Rustgi, A.K. p63 expression is associated with p53 loss in oral-esophageal epithelia of p53 deficient mice. Cancer Res., 61:6467-6473, 2001.
Burns, T.F., Fei, P., Scata, K.A., Dicker, D.T. and El-Deiry, W.S. Silencing of the novel p53 target gene, Snk/Plk2 leads to mitotic catastrophe in Paclitaxel (Taxol)-exposed cells. Mol. Cell. Biol., 23:5556-5571, 2003.
Burns, T.F., and El-Deiry, W.S. Microarray Analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol. Ther., 2:431-443, 2003.
Fei, P., Wang, W., Kim, S-H., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, W.G., Bernhard, E.J., and El-Deiry, W.S. Bnip3L is induced by p53 under hypoxia and its knockdown promotes tumor growth. Cancer Cell, 6:597-609, 2004.
Finnberg, N., Gruber, J.J., Fei, P., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., McKenna, W.G., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. DR5 knock-out mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol., 25:2000-13, 2005.
Grimberg, A., Coleman, C.M., Burns, T.F., Himelstein, B.P., Koch, C.J., Cohen, P., and El-Deiry, W.S. p53-dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J. Clin. Endocrinol. Metab. 90:3568-3574, 2005.
Grimberg, A., Coleman, C.M., Shi, Z., Burns, T.F., MacLachlan, T., Wang, W., and El-Deiry, W.S. Insulin-Like Growth Factor Binding Protein-2 is a Novel Mediator of p53 Inhibition of Insulin-Like Growth Factor Signaling. Cancer Biol. Ther., 5:1408-1413, 2006.
Abstracts
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated cell death receptor on chromosome 8p21. Second World Congress in Oncology. Athens, Greece, October 16-18, 1997.
Wu, G.S., Burns, T.F., McDonald III, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5, a DNA damage-inducible p53-regulated death receptor on chromosome 8p21. NATO Advanced Research Workshop at H. Lee Moffitt Cancer Center and Research Institute, Univ. of South Florida, December 5-9, 1997.
Wu, G.S., Burns, T.F., McDonald, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., and El-Deiry, W.S. Identification of KILLER/DR5 as a DNA damage-inducible p53-regulated cell receptor gene. 89th Annual meeting of the American Association for Cancer Research, New Orleans, LA, 1998.
Wu, G.S., Burns, T.F., Meng, R.D., and El-Deiry, W.S. Involvement of TRAIL death receptor signaling in p53-dependent apoptosis. 9th International p53 Workshop, Crete, May 9-13, 1998.
Meng, R.D., Burns, T.F., McDonald, E.R., III, Sheikh, M.S., Wu, G.S., Fornace, A.J., Jr., and El-Deiry, W.S. The TRAIL decoy receptor TRUNDD is induced by p53 overexpression but does not prevent KILLER/DR5- or p53-dependent colon cancer suppression. 90th Annual AACR Meeting, Philadelphia, Pennsylvania. Abstract No. 1124, April 1999.
Burns, T.F., Wu, G.S., Kao, G., Yen, T., and El-Deiry, W.S. p53-dependent induction of the TRAIL receptor KILLER/DR5 is conserved in mouse cells and is deficient in cells from patients with Ataxia Teleangiectasia. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 2869, April 1999.
Wu, G.S., Burns, T.F., Meng, R.D., and El-Deiry, W.S. p53-dependent induction of KILLER/DR5 in cells undergoing apoptosis but not cell cycle arrest. AACR 90th Annual Meeting, Philadelphia, Pennsylvania. Abstract No. 670, April 1999.
Burns, T.F., Bernhard, E.J., and El-Deiry, W.S. Real-time expression of p53 target genes and caspase activation in vivo after apoptotic stimuli. AACR 91st Annual Meeting, San Francisco, CA, April 2000.
Burns, T.F., Bernhard, E., and El-Deiry, W.S. Tissue-selective utilization of p53-target gene activation during apoptosis in-vivo. 10th International p53 meeting, Monterey, CA, April 2000.
Burns, T.F., Bernhard, E.J., and El-Deiry, W.S. The role of p53 and downstream genes in the response to genotoxic stress. 48th Annual Radiation Research Society meeting, Albuquerque, NM, May 2000.
Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., and El-Deiry, W.S. Caspase 9 inhibition allows TRAIL-induced killing of cancer cells while protecting normal human liver cells. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 1713, March 2001.
Burns, T.F., Dicker, D.T., and El-Deiry, W.S. Isolation of BI-1, c-FLIP-s, and Bcl-XL from a genetic screen of suppressors of TRAIL-induced apoptosis. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 2961, March 2001.
Grimberg, A., Coleman, C., MacLachlan, T.K., Burns, T.F., and El-Deiry, W.S. Insulin-like Growth Factor Binding Protein (IGFBP)-2 is Induced by p53. The Endocrine Society's 84th Annual Meeting, 2002.
Grimberg, A., Coleman, C., Burns, T.F., Himelstein, B.P., Koch, C., Cohen, P., and El-Deiry, W.S. p53-dependent and p53-independent Induction of IGFBP-3 by DNA Damage and hypoxia. The Endocrine Society's 84th Annual Meeting, 2002.
Burns, T.F., and El-Deiry, W.S. DNA damage-induced responses. European School of Hematology and MD Anderson Cancer Center 3rd International Conference on Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, Sintra, Portugal, 2002.
Sax, J.K., Burns, T.F., Murphy, M.E., and El-Deiry, W.S. Identification and characterization of TRAF4 as a p53-regulated gene. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Gruber, J.J., Fei, P., Finnberg, N., Rudolph, D., Bric, A., Burns, T.F., Ajuha, H., Page, R., Wu, G.S., Chen, Y., Bernhard, E.J., Lowe, S.W., Mak, T.W., and El-Deiry, W.S. KILLER/DR5 knock-out mice are compromised in radiation-induced apoptosis. AACR 95th Annual Meeting, Orlando, Florida, 2004.
Chapters and Reviews
Burns, T.F. and El-Deiry, W.S. The p53 pathway and apoptosis. J. of Cellular Physiology. 181:231-239, 1999.
Burns, T.F., and El-Deiry, W.S. Cell Death Signaling in Malignancy. In Signal Transduction in Cancer. Cancer Treatment and Research Series. Frank, D.A., Ed. Kluwer Academic Publishers, 115:319-343, 2003.

Zhaoyu Jin (Ph.D. in Pharmacology)
1999 - 2005, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Post-doc with Avi Ashkenazi at Genentech
2009 - Scientist, Genentech

Original Publications
Goldberg, G.S., Jin, Z., Ichikawa, H., Ohki, M., El-Deiry, W.S., and Tsuda, H. Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal significance of TRAIL in anoikis. Cancer Res., 61:1334-1337, 2001.
Jin, Z., and El-Deiry, W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of Simvastatin and TRAIL. Cell Cycle, 1:82-89, 2002.
Jin, Z., McDonald, E.R., III, Dicker, D.T., and El-Deiry, W.S. Deficient TRAIL Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-Induced Apoptosis. J. Biol. Chem., 279:35829-35839, 2004.
Ricci, M.S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D.T., and El-Deiry, W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol., 24:8541-8555, 2004.
Dicker, D.T., Kim, S-H., Jin, Z., and El-Deiry, W.S. Heterogeneity in Non-Invasive Detection of Apoptosis Among Human Tumor Cell Lines Using Annexin-V Tagged with EGFP or Qdot-705. Cancer Biol. Ther., 4:1014-1017, 2005.
Jin, Z., and El-Deiry, W.S. Distinct signaling pathways in TRAIL- versus TNF-induced apoptosis. Mol. Cell. Biol., 26:8136-8148, 2006.
Ricci, M.S., Kim, S-H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., Flaherty, K.T., Smith, C.D., and El-Deiry, W.S. Repression of TRAIL-induced Mcl-1 and CIAP2 expression by c-Myc or Bay 43-9006 (Sorafenib) sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66-80, 2007. Accompanying News Feature
Abstracts
Mitchell, K.O., Ricci, M.S., Miyashita, T., Dicker, D.T., Jin, Z.-Y., Reed, J.C., and El-Deiry, W.S. Bax as a transcriptional target and mediator of c-Myc-induced apoptosis. Gordon Research Conference on Cancer, Salve Regina University, Newport, RI, August 2000.
Jin, Z., and El-Deiry, W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of Simvastatin and TRAIL. AACR 92nd Annual meeting, New Orleans, LA, Abstract No. 2355, March 2001.
Jin, Z., and El-Deiry, W.S. Deficient TRAIL Death Receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. AACR 94th Annual Meeting, Toronto, Canada, 2003.
Chapters and Reviews
Jin, Z., and El-Deiry, W.S. Overview of cell death signaling pathways. Cancer Biol. Ther., 4:139-163, 2005.

Jue Judy Liu (Undergraduate Penn Vagelos Scholar)
2005 - 07, undergraduate student, El-Deiry Lab, University of Pennsylvania
Graduate admission to Harvard

Original Publications
Liu, J.J., Wang, W., Dicker, D.T., and El-Deiry, W.S. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol. Ther., 4:885-892, 2005.
Finnberg, N., Kim, S-H., Furth, E.E., Liu, J.J., Russo, P., Piccoli, D.A., Grimberg, A., and El-Deiry, W.S. Noninvasive Fluorescence Imaging of Cell Death in Fresh Human Colon Epithelia Treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol. Ther., 4:937-942, 2005.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Abstracts
Mayes, P.A., Liu, J.J., Jee, D., and El-Deiry, W.S. Overcoming Drug Resistance of Hypoxic Cancer Cells Using Hypoxia-Specific Small Molecule Sensitizers of TRAIL-Induced Apoptosis. 3rd International Conference on Tumor Progression and Therapeutic Resistance, Baltimore, MD, October, 2006.
Mayes, P.A., Liu, J.J., Kuribayashi, K., Jee, D.I.H., Dorsey, J.F., Dicker, D.T., Brown, J.M., Furth, E.E., and El-Deiry, W.S. Overcoming drug resistance of hypoxic cancer cells and tumors via stabilization of c-Myc protein through inhibition of GSK3. 99th Annual AACR meeting, San Diego, CA, April, 2008.

Robyn T. Sussman (B.S.)
2006 - 07, technical specialist, El-Deiry Lab, University of Pennsylvania
Graduate admission to Thomas Jefferson University

Original Publications
Sussman, R.T., Ricci, M.S., Hart, L.S., Sun, S-Y., and El-Deiry, W.S. Chemotherapy-resistant side-population (SP) of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol. Ther., 6:1490-1495, 2007.
Abstracts
Sussman, R.T., and El-Deiry, W.S. Chemotherapy resistant side population (SP) has a higher sensitivity to TRAIL than the non-SP and a 10-fold higher expression of TRAIL receptor DR4. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.

Patrick A. Mayes (Ph.D. in Pharmacology)
2006 - 09, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Post-doc with John Maris at Children's Hospital of Philadelphia
2010 - Principal Scientist, GSK
2011 - Investigator, Glaxosmithkline

Original Publications
Mayes, P.A., Campbell, L., Ricci, M.S., Plastaras, J.P., Dicker, D.T., and El-Deiry, W.S. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology and Therapy, 4:1068-1074, 2005.
Mayes, P.A., Dicker, D.T., Liu, Y.Y., and El-Deiry, W.S. Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing. BioTechniques, 45:459-464, 2008.
Kuribayashi, K., Krigsfeld, G., Wang, W., Xu, J., Mayes, P.A., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7:2034-2038, 2008.
Katz, S.I., Zhou, L., Ferrara, T., Wang, W., Mayes, P.A., Smith, C., and El-Deiry, W.S. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int. J. Oncol., 39:91-100, 2011.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Dolloff, N.G., Mayes, P.A., Hart, L.S., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Off-target Lapatinib activity derives from TRAIL death receptor up-regulation. Science Translational Medicine, 3:92-102, 2011.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Mayes, P.A., Liu, J.J., Jee, D., and El-Deiry, W.S. Overcoming Drug Resistance of Hypoxic Cancer Cells Using Hypoxia-Specific Small Molecule Sensitizers of TRAIL-Induced Apoptosis. 3rd International Conference on Tumor Progression and Therapeutic Resistance, Baltimore, MD, October, 2006.
Kuribayashi, K., Mayes, P.A., Kim, S-H., Rustgi, A.K., and El-Deiry, W.S. High-throughput bioluminescence screening for small molecules that overcome chemo- and TRAIL-resistance in human esophageal cancer cell lines. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Mayes, P.A., and El-Deiry, W.S. Failure of p53 to repress c-FLIP under hypoxic conditions contributes to TRAIL resistance of cancer cells. 98th Annual AACR meeting, Los Angeles, CA, April, 2007.
Abdulghani, J., Mayes, P.A., Dicker, D.T., Smith, C.D., Humphreys, R.C., and El-Deiry, W.S. Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Dolloff, N.G., Mayes, P.A., Dicker, D.T., Humphreys, R.C., and El-Deiry, W.S. Novel target of lapatinib enhances anti-tumor activity via TRAIL sensitization. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Mayes, P.A., Liu, J.J., Kuribayashi, K., Jee, D.I.H., Dorsey, J.F., Dicker, D.T., Brown, J.M., Furth, E.E., and El-Deiry, W.S. Overcoming drug resistance of hypoxic cancer cells and tumors via stabilization of c-Myc protein through inhibition of GSK3. 99th Annual AACR meeting, San Diego, CA, April, 2008.
Dolloff, N., Mayes, P., Dicker, D.T., and El-Deiry, W.S. Lapatinib enhances TRAIL sensitivity in colorectal cancer cells via a novel EGFR/HER2-independent mechanism involving JNK activation and DR5 up-regulation. 100th Annual AACR meeting, Denver, CO, April 2009.
Dolloff, N.G., Hart, L.S., Mayes, P.A., and El-Deiry, W.S. Dual GSK-3/CDK inhibitors induce multiple myeloma cell death and eliminate putative cancer stem cell populations. 101st Annual AACR meeting, Washington, D.C., April 2010.
Dolloff, N.G., Hart, L.S., Mayes, P.A., Dicker, D.T., Humphreys, R.C., Gilmer, T.M., and El-Deiry, W.S. Novel anti-tumor activity of lapatinib derives from off-target up-regulation of TRAIL death receptors. 101st Annual AACR meeting, Washington, D.C., April 2010.
Allen, J.E., Patel, L., Krigsfeld, G., Mayes, P.A., Wu, G.S., and El-Deiry, W.S. Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines. 101st Annual AACR meeting, Washington, D.C., April 2010.
Allen, J.E., Krigsfield, G., Mayes, P.A., Patel, L., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. The small molecule TIC10 has potent anti-cancer efficacy mediated by induction of TRAIL production in normal and tumor cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Dolloff, N.G., Mayes, P., Dicker, D., and El-Deiry, W. Sangivamycin-like molecules (SLMs) suppress the expression of oncogenic gene translocation products and induce apoptosis of multiple myeloma cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Dolloff, N.G., Mayes, P., Hart, L., Dicker, D., and El-Deiry, W.S. Off-target lapatinib activity upregulates TRAIL death receptors in colon cancer cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Chapters and Reviews
Mayes, P.A., and El-Deiry, W.S. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. The Cancer Journal, 12:247-249, 2006.
Kuribayashi, K., Mayes, P.A., and El-Deiry, W.S. What are Caspases 3 and 7 Doing Upstream of the Mitochondria? Cancer Biol. Ther. 5:763-765, 2006.

Luv Patel (Penn undegraduate Vagelos Scholar)
2007 - 10, undergraduate student, El-Deiry Lab, University of Pennsylvania
Post-doc with John Maris at Children's Hospital of Philadelphia

Original Publications
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Abstracts
Allen, J.E., Patel, L., Krigsfeld, G., Mayes, P.A., Wu, G.S., and El-Deiry, W.S. Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines. 101st Annual AACR meeting, Washington, D.C., April 2010.
Allen, J.E., Krigsfield, G., Mayes, P.A., Patel, L., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. The small molecule TIC10 has potent anti-cancer efficacy mediated by induction of TRAIL production in normal and tumor cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.

Lanlan Zhou (Ph.D. in Bioengineering at Penn)
2007 - 10, PhD thesis student, El-Deiry Lab, University of Pennsylvania
Post-doc in El-Deiry Lab at Penn State

Original Publications
Katz, S.I., Zhou, L., Chao, G., Smith, C.D., Ferrara, T., Wang, W., Dicker, D.T., and El-Deiry, W.S. Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol. Ther., 8:2406-2416, 2009.
Katz, S.I., Zhou, L., Ferrara, T., Wang, W., Mayes, P.A., Smith, C., and El-Deiry, W.S. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int. J. Oncol., 39:91-100, 2011.
Zhou, L., Wang, W., Dicker, D.T., Humphreys, R.C., and El-Deiry, W.S. Prediction of proapoptotic anti-cancer therapeutic response in-vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biol. Ther., 12:335-348, 2011.
Zhou, L., El-Deiry, W., Wang, W., Ingram, M.E., and Katz, S.I. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncol. Rep. 28:883-888, 2012.
Cheng, H., Hong, B., Zhou, L., Allen, J.E., Tai, G., Humphreys, R., Dicker, D.T., Liu, Y.Y., and El-Deiry, W.S. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle, 11:3312-3323, 2012.
Abstracts
Matthew, E.M., Zhou, L., Yang, Z., Lamparella, N., Liu, Y.Y., and El-Deiry, W.S. A Multiplexed Marker-based Algorithm for Diagnosis of Carcinoma of Unknown Primary (CUP) Using Circulating Tumor Cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Cheng, H., Hong, B., Zhou, L., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of C-Jun N-terminal kinase activation. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Zhou, L., Yang, Z., Baker, M., Dicker, D.T., and El-Deiry, W.S. Multispectral imaging of mismatch repair proteins in colorectal cancers and tumor cells isolated from blood. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Dolloff, N.G., Zhou, L., Peters, K., Navaraj, A., Allen, J.E., Das, A., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Zhou, L., Maidment, A., El-Deiry, W., Karunamuni, R., and Katz, S. Tumor growth inhibition following serial small animal CT. World Molecular Imaging Congress, Dublin, Ireland, Sept 5-8, 2012.
Zhou, L., Zhang, S., Dicker, D.T., Rehemtulla, A., and El-Deiry, W.S. Anticancer ERK kinase inhibitor screening with molecular imaging. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Zhang, S., Zhou, L., Hong, B., Warfel, N., van den Heuvel, A., Dicker, D.T., Kopelovich, L., and El-Deiry, W.S. A new small molecule compound restoring p53 pathway induces cell death via active p73 and degradation of mutant p53 in colorectal cancer cells. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Matthew, E.M., Gallant, J-N., Zhou, L., Yang, Z., Drabick, J.J., Truica, C.I., Lamparella, N.E., Dicker, D.T., and El-Deiry, W.S. Isolation, culture and immunophenotyping of live patient-derived circulating tumor cells. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Zhou, L., and El-Deiry, W.S. Multispectral fluorescence imaging. J. Nucl. Med. 50:1563-1566, 2009.

Joshua E. Allen (Ph.D. in Biochem & Mol Biol at Univ. of Pennsylvania)
2009 - 12, PhD thesis student, El-Deiry Lab, University of Pennsylvania and Penn State University
2012 - 13, , post-doctoral scientist, El-Deiry Lab, Penn State University
Director of Development, Oncoceutics, Inc

Original Publications
Allen, J.E., Hart, L.S., Dicker, D.T., Wang, W., and El-Deiry, W.S. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol. Ther. 8:2192-2203, 2009.
Mayes, P.A., Dolloff, N.G., Daniel, C.J., Liu, J.J., Hart, L.S., Kuribayashi, K., Allen, J.E., Jee, D.I.H., Dorsey, J.F., Liu, Y.Y., Dicker, D.T., Brown, J.M., Furth, E.E., Klein, P.S., Sears, R.C., and El-Deiry, W.S. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3beta and CDK1. Cancer Research, 71:5265-5275, 2011.
Wang, W., Gallant, J-N., Katz, S.I., Dolloff, N.G., Smith, C.D., Abdulghani, J., Allen, J.E., Dicker, D.T., Hong, B., Navaraj, A., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther., 12:229-238, 2011.
Gallant, J-N., Allen, J.E., Smith, C.D., Dicker, D.T., Wang, W., Dolloff, N.G., Navaraj, A., and El-Deiry, W.S. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther., 12:239-251, 2011.
Patel, A.S., Allen, J.E., Dicker, D.T., Peters, K.L., Sheehan, J.M., Glantz, M.J., and El-Deiry, W.S. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget, 2:752-760, 2011.
Allen, J.E., Ferrini, R., Dicker, D.T., Batzer, G., Chen, E., Oltean, D.I., Lin, B., Renshaw, M.W., Kretz-Rommel, A., and El-Deiry, W.S. Targeting TRAIL death receptor 4 with trivalent DR4 atrimer complexes. Molecular Cancer Therapeutics, 11:2087-2095, 2012.
Cheng, H., Hong, B., Zhou, L., Allen, J.E., Tai, G., Humphreys, R., Dicker, D.T., Liu, Y.Y., and El-Deiry, W.S. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle, 11:3312-3323, 2012.
Dolloff, N.G., Allen, J.E., Dicker, D.T., Aqui, N., Vogl, D., Malysz, J., Talamo, G., and El-Deiry, W.S. Sangivamycin-Like Molecule 6 (SLM6) exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9 (CDK9). Molecular Cancer Therapeutics, 11:2321-2330, 2012.
Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J-Y., Wu, G.S. and El-Deiry, W.S. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Science Translational Medicine, 5:50-62, 2013. Covered by Nature News.
Allen, J.E., and El-Deiry, W.S. Calcein-effluxing human colon cancer cells are enriched for self renewal capacity and depend on -catenin. Oncotarget, 4: 184-191, 2013.
Allen, J.E., Gallant, J-N., Dicker, D.T., Amin, S., Irby, R.B., Sharma, A.K., and El-Deiry, W.S. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PLoS ONE, 8(3): e59380. doi:10.1371/journal.pone.0059380 (published online March 12, 2013).
Abstracts
Allen, J.E., Patel, L., Krigsfeld, G., Mayes, P.A., Wu, G.S., and El-Deiry, W.S. Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines. 101st Annual AACR meeting, Washington, D.C., April 2010.
Allen, J.E., Krigsfield, G., Mayes, P.A., Patel, L., Dicker, D.T., Wu, G.S., and El-Deiry, W.S. The small molecule TIC10 has potent anti-cancer efficacy mediated by induction of TRAIL production in normal and tumor cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Abdulghani, J., Allen, J.E., Dicker, D.T., Smith, C.D., Humphreys, R.C., and El-Deiry, W.S. Sorafenib sensitizes solid tumors to TRAIL or TRAIL receptor agonist antibodies. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Peters, K.L., Allen, J.E., Dicker, D.T., Das, A., Joudeh, J., and El-Deiry, W.S. CTC profiling: Integration of biomarker analysis with current Veridex CellSearch technology. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Das, A., Allen, J.E., Dicker, D.T., Peters, K.L., Joudeh, J., and El-Deiry, W.S. Quantum Dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Gallant, J-N., Wang, W., Dolloff, N.G., Allen, J.E., and El-Deiry, W.S. Novel combinatorial Quinacrine cancer therapies for advanced colon cancer. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Das, A., Joudeh, J., Peters, K.L., Allen, J.E., Zheng, S., Dicker, D.T., Yang, Z., and El-Deiry, W.S. A population of metastatic colorectal cancer (mCRC) patients with radiologically proven liver metastasis and EpCAM expressing primary tumors show low circulating tumor cell counts by Veridex CellSearch. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Cheng, H., Hong, B., Zhou, L., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of C-Jun N-terminal kinase activation. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Das, A., Whitcomb, T.L., Allen, J.E., Dicker, D.T., Peters, K.L., El-Deiry, W.S. Isolation and characterization of circulating tumor cells in an orthotopic mouse model of colorectal cancer. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Allen, J.E., Krigsfeld, G., Patel, A.S., Wu, G.S., Dicker, D.T., and El-Deiry, W.S. Potent anti-tumor effects of TIC10 require Foxo3a and TRAIL gene upregulation. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Prabhu, V.V., Hong, B., Allen, J.E., Dicker, D.T., Navaraj1 A., Kopelovich, L., and El-Deiry, W.S. Anti-tumor effects of the p53-pathway restoring compound Prodigiosin in colorectal Cancer involve effects on apoptotic signaling, angiogenesis and cancer stem cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Dolloff, N.G., Zhou, L., Peters, K., Navaraj, A., Allen, J.E., Das, A., Dicker, D.T., Humphreys, R., and El-Deiry, W.S. Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Allen, J.E., Patel, A.S., Dicker, D.T., Sheehan, J.M., Glantz, M.J., and El-Deiry, W.S. Circulating tumor cells in the peripheral blood and cerebrospinal fluid of patients with central nervous system metastases. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Kaifi, J.T., Kunkel, M., Allen, J.E., Dicker, D.T., Peters, K.L., Das, A., Kimchi, E.T., Staveley-O’Carroll, K.F., and El-Deiry, W.S. Circulating tumor cell numbers in colorectal cancer patients with different metastatic spread patterns. American College of Surgeons’ 98th Annual Clinical Congress, Chicago, IL, Sept 30-Oct 4, 2012.
Patel, A.S., Allen, J.E., Dicker, D.T., Rizzo, K., Sheehan, J.M., Glantz, M.J., and El-Deiry, W.S. Monitoring circulating tumor cells in the cerebrospinal fluid and peripheral blood of patients with brain metastases undergoing intrathecal chemotherapy. 17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology. Washington DC.C., Nov 15-18, 2012.
Kaifi, J.T., Kunkel, M., Allen, J.E., Dicker, D.T., Das, A., Gusani, N.J., Reed, M.F., Kimchi, E.T., Staveley-O’Carroll, K.F., and El-Deiry, W.S. Presence of circulating tumor cells in patients with resectable colorectal cancer lung metastases is a potential indicator for extrathoracic disease. Academic Surgical Congress, New Orleans, LA, Feb 5-7, 2013.
Imperato, G.H., Allen, J.E., and El-Deiry, W.S. Characterization of TIC10, a novel small molecule inducer of TRAIL, in combination with chemotherapy for lymphoma in vitro. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Lim, B., Dolloff, N.G., Allen, J.E., Dicker, D.T. and El-Deiry, W.S. Lapatinib restores TRAIL-mediated apoptosis in TRAIL-resistant Triple Negative Breast Cancer (TNBC) through an off-target strategy that appears to be independent of increased death receptor expression. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Gokare, P., Finnberg, N., Allen, J., Dai, J., and El-Deiry, W.S. p53-dependent expression of the fluorouracil (5-FU) catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in mouse liver. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Prabhu, V.V., Allen, J.E., Dicker, D.T., Ding, Y., and El-Deiry, W.S. Therapeutic targeting of colorectal cancer stem cells by TRAIL-inducing small molecule TIC10. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Allen, J.E., Patel, A.S., Dicker, D.T., Sheehan, J.M., Glantz, M.J., and El-Deiry, W.S. Modeling circulating tumor cells in the peripheral blood and CSF of breast cancer patients. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Allen, J.E., and El-Deiry, W.S. Kinase library siRNA screen identifies KSR1 as a synergistic therapeutic target in combination with TIC10. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Chapters and Reviews
Allen, J.E., and El-Deiry, W.S. Circulating tumor cells and colorectal cancer. Curr. Colorectal Cancer Rep., 6:212-220, 2010.
Allen, J.E., and El-Deiry, W.S. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-XL inactivation. Gastroenterology, 141:430-434, 2011.
Allen, J.E., and El-Deiry, W.S. Targeting oncoproteins for molecular cancer therapy. The Molecular Basis of Human Cancer, Second Edition, Coleman, W.B., Editor, in press.
Faltas, B., Zeidan, A., Peters, K., Das, A., Joudeh, J., Navaraj, A., Dolloff, N.G., Harvey, H.A., Jiang, Y., Allen, J.E., Dicker, D.T., and El-Deiry, W.S. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J. Clin. Oncol., 29:2947-2948, 2011.
Allen, J.E., and El-Deiry, W.S. Regulation of the human TRAIL gene. Cancer Biol. Ther., in press, 2012.
Joudeh, J., Allen, J.E., Das, A., Prabhu, V., Farbaniec, M., Adler, J., and El-Deiry, W.S. Novel antineoplastics targeting genetic changes in colorectal cancer. Adv. Exp. Med. Biol. 779:1-34, 2013.

Jean-Nicolas Gallant (MSTP Program, Vanderbilt)
2010 - 12, technical specialist, El-Deiry Lab, Penn State University

Original Publications
Wang, W., Gallant, J-N., Katz, S.I., Dolloff, N.G., Smith, C.D., Abdulghani, J., Allen, J.E., Dicker, D.T., Hong, B., Navaraj, A., and El-Deiry, W.S. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther., 12:229-238, 2011.
Gallant, J-N., Allen, J.E., Smith, C.D., Dicker, D.T., Wang, W., Dolloff, N.G., Navaraj, A., and El-Deiry, W.S. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther., 12:239-251, 2011.
Allen, J.E., Gallant, J-N., Dicker, D.T., Amin, S., Irby, R.B., Sharma, A.K., and El-Deiry, W.S. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PLoS ONE, 8(3): e59380. doi:10.1371/journal.pone.0059380 (published online March 12, 2013).
Abstracts
Gallant, J-N., Wang, W., Dolloff, N.G., Allen, J.E., and El-Deiry, W.S. Novel combinatorial Quinacrine cancer therapies for advanced colon cancer. 102nd Annual AACR meeting, Orlando, FL, April, 2011.
Cheng, H., Gallant, J-N., Harouaka, R., Zheng, S., and El-Deiry, W.S. Ex vivo characterization of CTCs isolated using the FMSA device. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Gallant, J-N., Cheng, H., Harouaka, R., Zheng, S., and El-Deiry, W.S. In vivo drug sensitivity testing of CTCs isolated using the FMSA device. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Abdulghani, J., Gallant, J.N., Whitcomb, T., Dicker, D., Smith, C.D., Goldenberg, D., and El-Deiry, W.S. Quinacrine and sorafenib combination as potential therapy for anaplastic thyroid cancer. 103rd Annual AACR meeting, Chicago, IL, March 31-April 4, 2012.
Harouaka, R., Zhou, M-D., Khan, W.J., Yeh, T.Y-T.,, Zheng, S-Y., Gallant, J-N., Cheng, H., and El-Deiry, W.S. Flexible micro spring array (FMSA) device for viable CTC culture and drug efficacy testing. 1st Advances in Circulating Tumor Cells (ACTC) from Basic Research to Clinical Practice, Athens, Greece, Sept. 26-29, 2012.
Abdulghani, J., Gallant, J., Whitcomb, T., Dicker, D., Goldenberg, D., Smith, C.D., Finnberg, N., and El-Deiry, W.S. Quinacrine and sorafenib combination as potential therapy for anaplastic thyroid cancer. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.
Matthew, E.M., Gallant, J-N., Zhou, L., Yang, Z., Drabick, J.J., Truica, C.I., Lamparella, N.E., Dicker, D.T., and El-Deiry, W.S. Isolation, culture and immunophenotyping of live patient-derived circulating tumor cells. 104th Annual AACR meeting, Washington, DC, April 6-10, 2013.